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THESIS SUMMARY 
 
 
Coronary artery disease (CAD) is the most common type of cardiovascular disease and is 
one of the leading causes of morbidity and mortality globally. However, the pathogenesis of 
atherosclerosis which leads to CAD and results in heart attacks, heart failure and death is not 
well understood. In this context, studies have demonstrated a positive correlation between 
increased hepatic free fatty acids (FFAs) in atherosclerosis and CAD. Although CAD has well-
defined environmental risk factors, genome-wide association studies (GWAS) have 
demonstrated a genetic influence on CAD. Previous studies have shown that genetic variation 
within the human Y chromosome is associated with an increased risk of developing CAD 
independent of traditional cardiovascular risk factors; possibly through a modulating effect of 
an adaptive immunity and inflammatory response by macrophages in men. However, no Y 
chromosome-linked gene has been investigated in this disease so far. Long non-coding RNAs 
(lncRNAs) have recently gained focused attention as a new class of regulatory RNA molecules 
involved in cardiovascular function and associated disease, particularly long intergenic non-
coding RNAs (lincRNAs), the largest class within the lncRNA group so far. To date, Y 
chromosome-linked lincRNAs are poorly characterised and the potential link between these 
non-coding RNA molecules and CAD in men has not been investigated.  
In this context, I hypothesised that Y chromosome-linked lncRNAs may regulate pathways 
involved in lipid metabolism and trigger an over accumulation of FFAs in coronary arteries 
contributing to atherosclerosis, the underlying cause of CAD. The main objective of this thesis 
was to therefore further investigate the relationship between the Y chromosome, lncRNAs and 
CAD in light of the deficiencies within the literature to better understand the causative 
xviii 
 
molecular mechanisms of CAD pathophysiology in men.   
 
In my first study (Chapter 2), I identified for the first time through gene expression analysis 
(real-time PCR) the expression of the following (unannotated in PubMed) Y chromosome-
linked lincRNA transcripts: lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-
RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-
1:3, across 21 different normal, human tissues such as adipose, bladder, brain, cervix, colon, 
esophagus, heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, 
spleen, testes, thymus, thyroid, trachea, and white blood cells (WBCs) (leukocytes). I found 
that Y-linked lincRNAs were expressed at low levels (with the lowest CT number equal at 
24.5) with a high tissue-specificity for some. Also, the Y-linked RNA gene lnc-KDM5D-4 
was widely expressed across male tissues while the Y-linked RNA gene lnc-RBMY1J-1 was 
specific to the testes. Furthermore, this study presents the first evidence through gene 
expression analysis that the Y chromosome-linked lincRNA transcripts, lnc-KDM5D-4:1, lnc-
ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, and lnc-
RBMY1J-1:3 are expressed in male leukocytes. Hence, these lincRNAs could be potential 
non-protein coding gene candidates for CAD research. 
 
Knowing that the Y chromosome contributes to lipid levels in humans, to further explore the 
potential function of these Y-linked lincRNAs in CAD in men, I then studied their expression 
in a fatty liver context (steatosis-associated atherosclerosis) (Chapter 3). This was performed 
using the human hepatocellular liver carcinoma cell line, HepG2; the human model of liver 
cells in CAD research. This study showed for the first time that the Y-linked lincRNA 
transcripts lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, and lnc-
xix 
 
RBMY1B-1:4 were expressed in HepG2 cells, hence in hepatocellular carcinoma (HCC). 
Furthermore, this study demonstrated that lnc-KDM5D-4 is a nuclear-retained lincRNA using 
RNA fluorescence in situ hybridisation (RNA FISH), and is upregulated in palmitate-induced 
steatosis within hepatocytes (Fold Change = 2.16; p-value = 0.00216). The human 
Atherosclerosis RT2 Profiler™ PCR Array determined that the silencing of lnc-KDM5D-4 in 
HepG2 cells was triggering the upregulation of the inhibitor of apoptosis (IAP) gene 
baculoviral IAP repeat containing 3 (BIRC3) (Fold Change = 12.45, p-value = 0.000025), a 
well-described protein-coding gene expressed by vascular smooth muscle cells and 
macrophage foam cells of the inflamed vascular wall of atherosclerotic arteries. Furthermore, 
perilipin 2 (PLIN2), a gene known to be implicated in lipid metabolism, was also found 
upregulated. Therefore, this study provides the first evidence for the involvement of a Y-
chromosome-linked lincRNA, lnc-KDM5D-4, in steatosis-associated atherosclerosis and its 
retained-nuclear cellular localisation in human hepatocytes, suggesting a function which takes 
place in the cell nucleus and may play a role in regulating metabolic processes in the liver that 
are implicated in atherosclerosis. 
Having shown that a Y chromosome-linked lincRNA could be involved in the determination 
of lipid level and hence atherosclerosis in men, and to further explore the role of lnc-KDM5D-
4, the expression of this Y-linked lincRNA was studied in human coronary artery smooth 
muscle cells, especially in atherosclerotic coronary artery cells (Chapter 4). The expression of 
other non-coding RNAs were also studied such as the protein kinase, Y-linked, pseudogene 
(PRKY) - previously considered as a new functional candidate for the development of CAD. 
By analysing the transcriptome of human atherosclerotic and non-atherosclerotic coronary 
artery smooth muscle cells, I established evidence for the implication of the human Y 
xx 
 
chromosome in atherosclerosis and CAD. This study exposed the general underexpression of 
the transcripts from the Y chromosome in atherosclerotic cells implicating a loss or a 
repression of this chromosome in relation to CAD. Furthermore, this research determined by 
RNA sequencing a significant downregulation of seven transcripts from Y chromosome genes, 
including RPS4Y1, USP9Y, DDX3Y, TXLNGY, NLGN4Y and PRKY. RNA FISH determined 
the subcellular localisation of PRKY in smooth muscle cells by showing a nuclear and a 
cytoplasmic expression. Furthermore, qPCR gene expression analysis demonstrated that lnc-
KDM5D-4 is significantly downregulated in atherosclerotic cells in comparison to the non-
atherosclerotic cells.  
Together, these results showed that lnc-KDM5D-4 is a potential regulator of PLIN2 and BIRC3 
genes. Therefore, the downregulation of lnc-KDM5D-4 in atherosclerotic coronary artery 
smooth muscle cells suggests that this downregulation could be linked to the inflammation of 
the vascular smooth muscle cells in pathophysiology of CAD via the inhibition of apoptosis of 
the vascular smooth muscle cells triggered by the upregulation of BIRC3 in these cells. 
 
Overall, this study is the first to emphasise a potential involvement of a Y-specific lincRNA, 
called lnc-KDM5D-4, as a potential contributor to physiology in males. Lnc-KDM5D-4 knock-
down resulted in an upregulation of anti-apoptosis and lipid metabolism-related genes. 
Collectively, our data suggest that the male–specific lnc-KDM5D-4 may regulate key processes 
in cellular inflammation that trigger atherosclerosis and CAD in men. Accordingly, this data 
suggests that lnc-KDM5D-4 may provide a novel molecular biomarker for atherosclerotic 
arteries, and could potentially lead to revolutionary treatment modalities on Y-linked lincRNA 
as therapeutic agents to manipulate CAD-causing genes in men. 
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1. INTRODUCTION 
 
1.1  WHAT IS CORONARY ARTERY DISEASE (CAD)? 
 
1.1.1 Definition, epidemiology and physiology 
 
Coronary Artery Disease (CAD), also known as Coronary Heart Disease (CHD) or 
Ischemic Heart Disease (IHD), is the most common type of cardiovascular disease and is 
the major cause of morbidity and mortality in the world according to the latest report of 
the Global Burden of Disease (Global Burden of Disease [GBD] 2013 Mortality and 
Causes of Death Collaborators, 2015; World Health Organization [WHO], 2015). CAD 
disrupts the flow of oxygen-rich blood to the heart, making it the first cause of ‘years 
of life lost’ in developed countries and second in developing countries after pulmonary 
respiratory infections. Although life expectancy has been extended in the last decade, 
cardiovascular disease risk substantially increases with age, creating a heavy burden of 
morbidity and mortality (Berthold et al., 2011; Lakatta et al., 2003). In Australia, CAD 
is the major cause of death affecting around 1.4 million Australians and kills one of them 
every 24 minutes (Fuster et al., 2011; [WHO], 2015).  
 
CAD occurs when the arteries of the heart, which are known as the coronary arteries 
(Fig.I.1), are damaged from atheromatous plaques accumulating on the vessel arterial wall. 
Over time, this buildup of plaques progressively hardens and narrows the blood vessels, a 
process known as atherosclerosis (Duff, 1951) (Fig.I.2). As CAD is a multistep and 
chronic disease, the buildup of plaque occurs over many years and may start in childhood 
(Sakakura et al., 2013). If the atheromatous plaque ruptures, fragments stick to the site of the 
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injury and clump together to form blood clots, which can further narrow the arteries and worsen 
the angina. If a clot becomes large enough, it can mostly or completely block the artery 
resulting in a heart attack, stroke, or even sudden death (Roger et al., 2012). The American 
Heart Association (2014) classifies atherosclerotic lesions into six different types (Lee & 
Shah, 2015) (Fig.I.2). 
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Figure I.1: Heart with muscle damage and a blocked artery. ( A) Location of the 
heart in the body. (B) Overview of heart and coronary artery showing damage (dead heart 
muscle) caused by a heart attack. (C) Cross-section of the coronary artery with plaque 
buildup and a blood clot (Taken from the National Heart, Lung, and Blood Institute, U.S., 
2013). 
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Figure I.2: Atherosclerotic lesions and CAD plaque progression. Beginning with 
isolated foam cells, lesions develop into fatty streaks and subsequently atheroma. 
Calcification (in white) begins to occur in fibroatheroma formations all the way to 
complicated lesions such as thrombi. It is at this point that subjects enter the clinical phase 
of atherosclerosis where there is risk of plaque rupture, leading to either thrombotic 
occlusion or severe stenosis (Adapted from Lee & Shah, 2015). 
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1.1.2 CAD risk factors 
 
By definition, the term “risk factor” describes those characteristics found to be related to 
the subsequent occurrence of CAD. This term includes modifiable lifestyle, biochemical 
and physiological characteristics, as well as unmodifiable personal characteristics such as 
age, sex and family history of CAD.  
CAD is a multifactorial and complex late-onset disease which originates from a 
complicated interplay of environmental and genetic factors. The major risk factors are 
listed below and can be classified as follows (Runge et al., 2010): 
 
Conventional risk factors 
 Aging 
 Hereditary (family history of early heart disease)  
 Sex 
 
Modifiable risk factors 
 Lipid disturbances (High blood cholesterol levels - high levels of low-
density lipoprotein (LDL) and low level of high- density lipoprotein 
(HDL)) 
 Hypertension (high blood pressure) 
 Cigarette smoking  
 Type 2 diabetes 
 Obesity 
 Lack of physical activity 
 Mental stress and depression 
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Non-traditional or novel risk factors 
 
-High blood levels of the following are considered to be risk factors for CAD: 
 C-reactive protein: High levels are related to the presence of inflammation 
and, according to some research results, may be associated with an 
increased risk of CAD development and heart attack (Arroyo-Espliguero et 
al., 2004). 
 Lipoprotein (a)  
 Homocysteine 
 Fibrinogen 
 
-Medical conditions that can contribute to CAD include the following: 
 Chronic inflammatory diseases affecting connective tissues (e.g. lupus, 
rheumatoid arthritis) (Chung et al., 2005; Manzi et al., 1997) 
 Human immunodeficiency virus (HIV) infection (Sani, 2008) 
 Xanthelasma palpebrarum disease (Dey et al., 2013) 
 
-The following are also considered to be risk factors: 
 Oophorectomy (Kritz-Silverstein et al., 1997) 
 Lack of sleep (King et al., 2008; Sharma et al., 2014) 
 Low serum testosterone levels (Khaw et al., 2007; Malkin et al., 2010; 
Ponikowska et al., 2010)  
Risk factors could be related to one another. For instance, family history may involve elevated 
LDL-cholesterol. Also, although some evidence now suggests that low testosterone levels 
should be considered an independent cardiovascular risk factor (Jones, 2010), the causality 
of the relationship between low testosterone levels and vascular disease is still unclear 
(Araujo et al., 2011; Kelly & Jones, 2013).  
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Finally, a lot of cardiometabolic risk factors facilitate the development of atherosclerosis, 
however the precise underlying mechanisms remain disputed.  
  
1.1.3 Pathophysiology 
 
Currently the pathogenesis of CAD is not fully understood with the molecular mechanisms 
that promote CAD in individuals affected by these environmental factors remaining unclear. 
Atherosclerosis is driven by a chronic inflammatory process, elicited in part by 
subendothelial lipoprotein retention and involving innate and adaptive immune responses 
(Williams & Tabas, 1995). Lipid disturbances and other risk factors are thought to cause 
endothelial injury resulting in monocyte adhesion and migration to the intima, as well as 
the release of cytokines and growth factors. These include platelet-derived growth factor 
(PDGF) which leads to smooth muscle cell migration to the intima and proliferation 
(Fig.I.3). The recruitment of activated macrophages and T cells into and within the 
atherosclerotic lesions is guided by endothelial leukocyte adhesion molecules and 
chemoattractants (Kumar et al., 2005). Within the intima, smooth muscle cells produce an 
extracellular matrix including collagen and proteoglycans. LDL particles travelling in the 
blood and carrying cholesterol and triglycerides from the liver to other body tissues get 
through the endothelium layer due to their size and density, and become oxidised. After 
migration to the sub-endothelial space, monocytes differentiate into macrophages which are 
then able to ingest oxidized-LDL, forming specialised foam cells. Macrophages are not able 
to process the oxidized-LDL and ultimately grow and rupture depositing a greater amount 
of oxidized cholesterol into the artery wall. This triggers the recruitment of more 
monocytes, thus increasing the inflammation and continuing the cycle. This inflammation 
leads to subendothelial accumulation of fatty substances called atheromatous plaques 
(Kumar et al., 2005). The pathology of atherosclerosis is apparently indistinguishable and 
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independent of the risk factor, or combination of risk factors associated with disease 
progression. This observation suggests that the pro-atherogenic pathways associated with 
each risk factor converge on a common molecular mechanism (Zeadin et al., 2013).  
Furthermore, it has been shown that the Herpes virus infection is associated with 
atherosclerosis (Hsu et al., 1995), with cytomegalovirus infection also being a risk factor for 
increased arterial blood pressure, and a co-factor in aortic atherosclerosis (Cheng et al., 2009). 
As many as 50% of patients with atherosclerosis lack currently identified risk factors, an 
observation suggesting that additional factors predisposing to atherosclerosis are as yet 
undetected (Genco et al., 2005). 
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Figure I.3: Schematic diagram of hypothetical sequence of cellular interactions in 
atherosclerosis. Hyperlipidaemia and other risk factors trigger endothelial dysfunction 
resulting monocyte adhesion and migration to the intima, as well as a release of 
cytokines and growth factors which lead to smooth muscle cells migrating to the intima 
and proliferating. Also, LDL particles travelling in the blood pass through the endothelium 
and become oxidized. Then, macrophages absorb the oxidised-LDL forming specialised 
foam cells, grow, and then rupture depositing a greater amount of oxidized-LDL in the 
artery wall (Taken from Kumar et al., 2005).  
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1.2 THE HUMAN Y CHROMOSOME 
 
1.2.1 Structure and function 
 
The human Y chromosome is one of the two sex chromosomes, also known as allosomes. 
Humans have 23 pairs of chromosomes – 22 autosome pairs and 1 sex determining pair (X 
and Y). Females have two X chromosomes; whereas males have one X and one Y 
chromosome. Of all the chromosomes in human genome, the haploid Y chromosome 
contains the smallest number of genes.  To date, there is 200 genes on the Y but only 27 
proteins are transcribed (Bethesda, 2015; Skaletsky et al., 2003). Its major part, the male-
specific region (MSY) which constitutes ≈95% of its length (Fig.I.4) does not recombine 
with the other sex chromosome (the X chromosome) during meiosis and is inherited as an 
indivisible unit from fathers to sons (Skaletsky et al., 2003). The fundamental biological role 
of the human Y chromosome is thought to impart male characteristics notably through the 
gene SRY which triggers testis development (Graves et al., 2006). 
As a result of there being a lesser abundance of the Y chromosome in the human population 
and its lack of recombination, it is generally excluded from genome-wide association studies 
(GWAS) (Bloomer et al., 2014), thus there is little data available on the role it plays in 
human health and disease.  
 
1.2.2 Research history 
 
It is believed that the human sex chromosomes derived from an ancestral pair of autosomes 
(Ohno, 1967) approximately 29-32 million years ago (Ross et al., 2005) with the Y 
chromosome undergoing a series of inversions that prevented crossing over with the X 
chromosome, and acquiring a sex determining function (Lahn & Page, 1999; Rice, 1996). 
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Over time, the Y chromosome has degenerated so that regular crossover with the X 
chromosome is restricted to specialised XY-homologous pseudoautosomal regions (Rosser 
et al., 2009). Other XY-homologous loci (known as gametologs (Garcia-Moreno & Mindell, 
2000) consist of 25 genes with functional copies on both sex chromosomes and are regarded 
to be evolutionary isolated (Ross et al., 2005). Although gene conversion amongst sequences 
on the MSY occurs frequently (Adams et al., 2006; Bosch et al., 2004; Rozen et al., 2003; 
Skaletsky et al., 2003), there is no evidence of recombination of the MSY with other 
chromosomes (Rosser et al., 2009).  
It is believed that during this evolutionary process, the X chromosome maintained most of 
its ancestor’s genes, whereas the Y chromosome lost them (Graves & Schmidt, 1992; 
Jegalian & Page, 1998). In more recent times, research into the Y chromosome can be 
categorised into three eras - Mendelian examination of human family trees; Y chromosome 
as a genetic wasteland; and the application of recombinant DNA and genomic technologies 
to the Y chromosome (Skaletsky et al., 2003). 
First era – Mendelian examination of human family trees 
The Mendelian examination of family trees era was able to conclude that the Y chromosomal 
genes are responsible for scaly skin and hairy ears amongst other traits (Skaletsky et al., 
2003), and by 1950 at least 17 Y-linked traits had been reported from these studies of human 
pedigrees (Stern, 1957). 
Second era – Y chromosome as a genetic wasteland 
The second era focused on the view that the Y chromosome is actually just a genetic 
wasteland. These views are based on new evidence that exposed critical flaws, thus 
disproved the results of the previous studies (Stern, 1957). Further studies were completed 
during the 1950’s and 1960’s that were able to demonstrate that the Y chromosome carries 
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a sex-determining gene (considered to be an exception on a generally desolate chromosome) 
(Ford et al., 1959; Jacobs & Strong, 1959). It was proposed that the X and Y chromosomes 
had evolved from ordinary autosomes, with the X chromosome retaining most of its 
autosomal content, however the Y chromosome lost everything except the gene involved in 
sex determination (Ohno, 1967). 
Third era – Application of recombinant DNA 
The third (and present) era focuses on the application of recombinant DNA and genomic 
technologies to the Y chromosome (Skaletsky et al., 2003), enabling molecularly based 
conclusions about its genes. DNA studies of people with partial Y chromosomes, Turner 
syndrome, gonadal sex reversal, spermatogenic failure and graft rejection have exacerbated 
our understanding of the biological functions of the Y chromosome in recent decades (Vogt 
et al., 1997). The start of the Y chromosome consists of a short sequence which is also shared 
with the X chromosome, the remaining 95% has been described as a mosaic of complex and 
interrelated sequences (Skaletsky et al., 2003). During X to Y gene conversion, the Y 
chromosome is uniquely affected, which has been proposed to be advantageous in increasing 
genetic diversity and resisting degradation during evolution (Trombetta et al., 2009). 
 
1.2.3 Human Y chromosome and genetics of CAD 
 
It is now well known that the heritability as risk factor for CAD should not be excluded from 
studies into its etiology. CAD is a highly heritable trait, with genetic and environmental 
factors accounting for similar proportions of individual susceptibility (Kathiresan et al., 
2012; Stylianou et al., 2012). According to the Framingham Offspring Study, the age-
specific incidence of CAD is increased approximately two-fold in participants with a family 
history of premature disease (Lloyd-Jones et al., 2004). To date, GWAS have been able to 
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identify more than 90 genes within different chromosomes that are involved in the 
pathogenesis of CAD (as summarised in Appendix 1.1) (Butterworth et al., 2011; Clarke et 
al., 2009; Lu et al., 2012; McPherson, 2014; Peden et al., 2011; Peden & Farrall, 2011; 
Roberts et al., 2012; Schunkert et al., 2011; Soranzo et al., 2009; Zdravkovic et al., 2002). 
It appears that majority of these risk loci harbor genes previously unknown to be involved 
in atherosclerosis. In fact, just 15% of the identified CAD risk loci work through known risk 
factors, such as lipids and blood pressure, implying that key pathways leading to CAD are 
yet to be discovered (McPherson, 2014). 
 
The most genomic susceptibility locus known to date for CAD heritability was identified 
within the intergenic non-coding region of chromosome 9p21 by McPherson et al, in 2007 
(McPherson et al., 2007). This locus contains a long non-coding ribonucleic acid (lncRNA), 
referred to as antisense non-coding RNA in the INK4 locus, commonly known as ANRIL, 
as reviewed in (Congrains et al., 2013; Holdt & Teupser, 2012). So far, ANRIL is the most 
replicated marker of CAD, independent from the conventional risk factors and its expression 
is correlated with atherosclerotic lesions (Schonrock et al., 2012). 
Subsequent studies revealed that this locus is related to a broad spectrum of vascular 
phenotypes, including CAD and myocardial infarction (Helgadottir et al., 2007; Samani et 
al., 2007; Zdravkovic et al., 2002), coronary artery calcification (O’Donnell et al., 2011), 
peripheral artery disease (Cluett et al., 2009; Murabito et al., 2012), and abdominal aortic 
aneurysm (Helgadottir et al., 2008). However, despite the potential importance of this 
lncRNA to vascular disease, the pathophysiology underlying the link between ANRIL and 
CAD currently remains unknown.  
Taking the aforementioned studies into consideration, it has been shown that the increased 
risk for CAD cannot be fully explained through the conventional risk factors.  
16 
 
There is data that links the Y chromosome to cardiovascular diseases. CAD is predominately 
associated with males (Madaric et al., 2005; Rosamond et al., 2007) with a 3:1 ratio of men 
to women (Australian Institute of Health and Welfare, 2011) with males commonly 
developing CAD nine years earlier than women (Yusuf et al., 2004). Moreover, polysomy 
of the Y chromosome (XYY karyotype) was linked to increased cardiovascular mortality 
(Higgins et al., 2007) with associations found between single nucleotide polymorphisms 
(SNPs) of the MSY and blood pressure, circulating concentrations of total cholesterol, LDL 
cholesterol, proatherogenic B-phenotype of LDL cholesterol molecules, and paternal history 
of coronary artery disease (Charchar et al., 2002; Charchar et al., 2004; Ellis et al., 2000; 
Shankar et al., 2007). Although not all studies have replicated these associations, the 
accumulated evidence lends support to the notion that genetic variation within the MSY 
could play a part in determining cardiovascular risk in men (Charchar et al., 2003; Ely et al., 
2010). 
 
Due to the haploid nature of the Y chromosome, the usual methods of analysis (such as 
GWAS) cannot be employed to investigate variations, and this is the reason why the Y 
chromosome is routinely excluded from large-scale GWAS. The Y chromosome is therefore 
the most underexplored portion of the human genome to date. To bypass this difficulty, 
Charchar et al. (2012) performed an analysis of the Y chromosome phylogenetic tree. This 
strategy is defined by a series of biallelic SNPs which enable the MSY to be partitioned into 
20 major haplogroups (non-recombining portions of DNA (Y Chromosome Consortium, 
2002)) that descend from a common ancestor, Y-chromosomal Adam (Jobling et al., 2003). 
This study was the first to evaluate associations between main European Y chromosome 
lineages and coronary artery disease, as well as its underlying risk factors. Results showed 
that men who inherit haplogroup I (one of the most common Y chromosome types in Europe) 
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from their male ancestors have a 50% increased risk of developing coronary artery disease 
compared to men with other Y chromosome haplogroups. This study also demonstrated that 
the effect of haplogroup I on CAD is not mediated by traditional cardiovascular risk factors 
(such as age, body-mass index, blood pressure, lipids, diabetes, smoking, alcohol 
consumption, socioeconomic status, or circulating concentrations of C-reactive protein) but 
might be mediated through a genetically programmed profile of immunity and response to 
inflammation. This makes haplogroup I of the Y chromosome one of the strongest common 
genetic risk factors of CAD known to date (Charchar et al., 2012). 
 
To confirm these findings and identify the causative variants underlying the increased 
susceptibility to CAD in carriers of haplogroup I, a total of 1988 biologically unrelated men 
from 4 white European populations were genotyped, using 11 Y chromosome SNPs and 
classified into the 13 most common European haplogroups (Bloomer et al., 2013). The 
results of this study confirmed that haplogroup I of the Y chromosome, which has previously 
been linked to an increased risk of CAD, is not associated with conventional cardiovascular 
and metabolic risk factors in young men from the general white European population. This 
study also showed for the first time that CAD predisposing haplogroup I of the Y 
chromosome is associated with the downregulation of two MSY genes; ubiquitously 
transcribed tetratricopeptide repeat, Y-linked gene (UTY) and protein kinase, Y-linked, 
pseudogene (PRKY) within macrophages. The UTY gene encodes a protein containing 
tetratricopeptide repeats involved in protein-protein interactions. This protein acts as an 
immune related minor histocompatibility antigen that may induce graft rejection of male 
stem cell grafts (Mortensen et al., 2012; Skaletsky et al., 2003). The dysregulated expression 
of this gene in macrophages of subjects with haplogroup I may lead to increased risk of CAD 
(Fig.I.4). This is also based on an emerging role for UTY in both the immune system 
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(Bloomer et al., 2013), haematopoiesis (Thieme et al., 2013) and cardiovascular system 
development (Soehnlein et al., 2013; Welstead et al., 2012), which are important processes 
that contribute to the development of CAD (Eriksson et al., 2003; Soehnlein et al., 2013).  
Recently published data by Wang et al. (2012) on the role on UTY revealed that it is essential 
for progression of cardiac development and that it associates with cardiovascular specific 
transcription factors to regulate downstream target genes. Data on Uty mutant mice by 
Shapargel et al. (2012) show that Uty is able to regulate gene activity through demethylase 
independent mechanisms.  
Regarding PRKY, little literature is available in regards to its function. PRKY is only known 
to account for approximately 30% of all cases of sex reversal disorder in XX males and XY 
females due to crossing over with PRKX, the X chromosome homologue (Jobling et al., 
1998; Nakashima et al., 2013; Schiebel et al., 1997; Weil et al., 1994). To date, the study by 
Bloomer, et al. (2013) is the only known study reporting on a potential relationship between 
PRKY and CAD. 
 
So far, no additional studies have been published on PRKY or other Y-linked lncRNAs in 
humans on CAD. Despite a large advance in our knowledge of CAD genes from GWAS 
studies, the studies of the Y chromosome linked-genes in CAD are still sparse. The 
involvement and function sex chromosome genes in an atherosclerotic context need to be 
further elucidated.  
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Figure I.4: Schematic diagram of hypothetical links between a genetic variation within 
the MSY and the fatty plaque build-up in CAD. Independently of traditional risk factors, 
a genetic variation within the male-specific region of the human Y chromosome (MSY) 
resulting in a downregulation of ubiquitously transcribed tetratricopeptide repeat, Y-linked 
gene (UTY) and protein kinase, Y-linked, pseudogene (PRKY) in macrophages of men with 
haplogroup I would trigger an endothelial dysfunction resulting in macrophages migrating 
to the intima. The release of cytokines and growth factors then leads to smooth muscle cells 
migrating to the intima and proliferating. Also, LDL particles travelling in the blood pass 
through the endothelium and become oxidized. Finally, the take-up of oxidised-LDL by 
macrophages transformed them into specialised foam cells which grew in size and rupture, 
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depositing a greater amount of oxidized-LDL in the artery wall. SRY: sex-determining 
region of the Y chromosome. Regions of the human Y chromosome: AZFa, azoospermia 
factor a; AZFb, azoospermia factor b; AZFc, azoospermia factor c; PAR1, pseudo-autosomal 
region 1; PAR2, pseudo-autosomal region 2 (Taken from Molina et al., 2016). 
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1.3 WHAT ARE LONG NON-CODING RNAS (LNCRNAS)? 
 
1.3.1 Introduction to the non-coding RNA world 
 
The conventional view of gene regulation in biology has centered on protein-coding genes 
via the central dogma “DNA makes mRNA makes protein”. This dogma has been 
established by the British biophysicist Francis Crick (Crick, 1970) who received the 1962 
Nobel Prize for Physiology or Medicine for his findings of the molecular structure of 
deoxyribonucleic acid (DNA). However, today, there is some controversy about this dogma 
notably with the discovery of regulatory non-coding RNAs (ncRNAs) (Li et al., 2011).  
 
Over the past ten years, new methods including RNA sequencing and DNA tiling arrays 
(high-density oligonucleotide-based whole-genome microarrays) have enabled the 
identification and characterization of the human transcriptome. These techniques 
completely changed our understanding of genome organization and content, and also 
revealed that a much larger part of the human genome, initially referred to as “junk DNA” 
(Ohno, 1972) is transcribed into RNA than was previously assumed (Carninci et al., 2005; 
Mattick, 2003; Mortazavi et al., 2008; Nagalakshmi et al., 2008; Okazaki et al., 2002; 
Wilhelm et al., 2008). The sequencing of the human genome revealed that there are 
solely ∼20,000 protein-coding genes representing less than 2% of total genomic sequence 
(Birney et al., 2007). Also, evidence suggests that the evolution of developmental processes 
regulating the complexity of the organism is mainly due to the expansion of the regulatory 
potential of the non-coding portions of the genome (Mattick, 2004). The extent of intronic 
and intergenic non-coding sequences in genomes does increase with developmental 
complexity, suggesting that these sequences may contain increasingly elaborate regulatory 
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information (Taft et al., 2007) (Fig.I.5). For example, the proportion of non-protein-coding 
DNA is less than 25% in prokaryotes, more than 60% in plants, and metazoans and 
98.5% in humans (Mattick, 2011).  Moreover, many non-coding regulatory elements are 
transcribed into non-coding RNAs (ncRNAs), suggesting that these ‘junk’ ncRNAs could 
actually play significant regulatory roles in complex organisms (Carninci et al., 2005). 
 
This recent explosion of information about the ncRNA world has demonstrated the 
importance of these molecules in the regulation of multiple major biological processes 
in mammals (Mattick, 2009), in Drosophila melanogaster (Rajendra et al., 2001), in 
plants like Arabidopsis (Ben et al., 2009) and in fungi such as Saccharomyces cerevisiae 
(Camblong et al., 2007). Therefore, these results reveal that the range, depth, and 
complexity of the human transcriptome that is far from fully characterised (Dimond, 2014). 
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Figure I.5: The relationship between biological complexity and genome composition. In 
this plot, the 73 organisms with a previously defined number of distinct cell types (e.g., 
relative biological complexity) are shown as pairs of data points, with one depicting total 
protein-coding sequence bases (red) and one total non-protein-coding bases (blue) which 
cumulatively give the total genome size (x-axis). Non-protein-coding sequence increases 
exponentially with the number of distinct cell types, while protein-coding sequence is 
asymptotic. Note that the intersection of the protein-coding and non-protein-coding data 
sets occurs among simple multicellular organisms (Taken from Liu et al., 2013). 
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1.3.2 Non-coding RNA classes 
 
The transcriptome of a eukaryotic cell contains different types of ncRNAs that can be 
divided into two main classes (Table I.1): structural and regulatory ncRNAs. Structural 
ncRNAs include RNA molecules that are usually constitutively expressed such as ribosomal 
and transfer RNAs. Regulatory ncRNAs can be classified into three major classes based on 
transcript size: small, medium and long non-coding RNAs (lncRNAs) (Iaconetti et al., 
2013). Regarding the lncRNA group, the different classes of lncRNAs are not exclusive. 
For instance, some authors include pseudogenes in the lncRNA class, others do not. Also, it 
is not yet clear whether and how the classification reflects biological function (Atkinson 
et al., 2012).  Long intergenic ncRNA, also called long intervening ncRNA, represent the 
largest class within the lncRNA group so far (Chowdhury et al., 2013). 
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Non-coding RNAs Symbol 
Structural ncRNAs 
Transfer RNA tRNA 
Ribosomal RNA rRNA 
Regulatory 
ncRNAs 
Short 
ncRNAs 
Micro RNA miRNA 
PIWI-interacting RNA piRNA 
Short interfering RNA siRNA 
Medium 
ncRNAs 
Small nucleolar RNA snoRNA 
Promotor upstream transcripts PROMPTs 
Transcription initiation RNA tiRNA 
Long 
ncRNAs 
Long intergenic ncRNA lincRNA 
Enhancer-like ncRNA eRNA 
Transcribed ultra-conserved regions T-UCRs 
Natural antisense transcripts NATs 
Promotor-associated long RNAs PALRs 
Pseudogenes None 
 
Table I.1: Classes of non-coding RNAs. (Adapted from Iaconetti et al., 2013). 
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1.3.3 LncRNA definition, history and specifications 
 
By definition, long non-coding RNAs are transcribed RNA molecules, greater than 200 
nucleotides in length (Carninci et al., 2005), which do not encode proteins (Guttman et al., 
2013), and with a little or no open reading frame (ORF) (Lyle et al., 2000; Perkel, 2013). 
LncRNAs have been known in literature since the early 1990’s when the human H19 gene 
(imprinted maternally expressed transcript (non-protein coding)) was cloned and sequenced 
showing that the H19 RNA was not a classic mRNA, but in fact a lncRNA (Brannan et al., 
1990). From this discovery, the extent of lncRNA transcription was revealed in a study 
using large-scale sequencing of cDNA libraries using mouse model (Okazaki et al., 
2002). This study determined that a large proportion of the mammalian transcriptome does 
not code for proteins, and thus defined lncRNAs as a significant class of transcripts.  
 
In contrast to mRNAs or miRNAs, lncRNAs are poorly conserved across species (Saxena 
& Carninci, 2011), which strengthens the role of lncRNAs in the increasing complexity of 
species (Pang et al., 2006). One unique characteristic associated with lncRNAs is that they 
exhibit richer tissue specificity when compared to coding genes and small regulatory 
ncRNAs (Cabili et al., 2011). While most mRNAs are exported to the cytoplasm for 
translation, a lot of lncRNAs are now known to be retained in various sub-nuclear 
compartments suggesting that such RNAs may have a potential function in the compartment 
of which they are localized. In eukaryotic cells, they have a subcellular localisation; 
nucleus and/or cytoplasm (Clark & Mattick, 2011) which play a critical role in organising 
nuclear 3D chromatin structure and architecture as discussed in sections 3.2 and 3.5. 
Furthermore, their expression level is generally 10-20 times lower than transcripts produced 
from the protein coding genes, so this can be challenging with the current techniques to 
study them compared to the other classes of RNA (Bassett et al., 2014). LncRNAs possess 
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some signatures of mRNAs, including 5’capping, splicing, may or may not be 
polyadenylated (Cabili et al., 2011; Carninci et al., 2005, Chew et al., 2013) and are even 
associated with polysomes (Guttman et al., 2013). Moreover, they are transcribed by RNA 
polymerase II from either strand within a protein-coding locus (Kapranov et al., 2007), and 
are associated with epigenetic signatures common to protein-coding genes such as 
trimethylation of histone 3 lysine 4 (H3K4me3) at the transcriptional start site, and 
trimethylation of histone 3 lysine 36 (H3K36me3) throughout the gene body (Guttman 
et al., 2009). Furthermore, lncRNA genes are shorter than coding genes and are composed 
of a unique structure of usually 1-2 exons. 
LncRNA numbers exceed those of protein-coding genes in the human genome. The 2014 
update of the NONCODE database, the number of entries reached 56,018 and 46,475 
lncRNA genes for human and mouse, respectively (Xie et al., 2014). Recently, more than 
58,000 lncRNA genes have been identified in the human genome, of which there are less 
than 22,000 protein-coding genes (Iyer et al., 2015) (Fig.I.6).  
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Figure I.6: Characterisation of the human transcriptome and number of lncRNA. Pie 
chart of composition and quantities of lncRNA, transcripts of unknown coding potential 
(TUCP), expressed pseudogene, read-through, and protein-coding genes. Results obtained 
from 7,256 RNA sequencing libraries from tumors, normal tissues, and cell lines 
comprising over 43 terabases of sequence from 25 independent studies (Taken from Iyer et 
al., 2015). 
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1.3.4 Organisation and location in the genome 
 
The current landscape of the mammalian genome is described as numerous foci of 
transcription that are separated by long stretches of intergenic space (Carninci et al., 
2005). While lncRNAs are located and transcribed within the intergenic stretches, the 
majority are transcribed as complex, interlaced networks of overlapping sense and antisense 
transcripts that often include protein-coding genes (Kapranov et al., 2007). LncRNAs are 
most commonly classified according to their proximity to protein coding genes, and as a 
result, they are generally placed into six categories (Fig.I.7). Intergenic lncRNAs 
(lincRNAs) are located between two protein-coding genes; the majority of lncRNAs belong 
to this category. Intronic lncRNAs are located within introns of protein-coding genes. 
Bidirectional promoter lncRNAs are transcribed within 1kb of promoters in the opposite 
direction from the protein-coding transcript. Enhancer lncRNAs (elncRNAs) are generally 
<2kb and transcribed from enhancer regions of the genome. Sense lncRNAs are transcribed 
from the sense strand of protein-coding genes, and can overlap introns and part or all of the 
exon. Antisense lncRNAs are transcribed from the antisense strand of protein-coding genes, 
and can overlap an exon of the protein-coding gene in the sense strand, an intron, or both 
(Mattick, 2009; Mercer et al., 2009; Ponting et al., 2009). 
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Figure I . 7: Genomic organisation of lncRNAs. (a) Intergenic, when lncRNA lies 
within the genomic interval between two protein-coding genes. (b) Intronic, when lncRNA 
is located within an intron of a protein-coding gene.  (c) Bidirectional, when lncRNA is 
located within 1kb of promoters in the opposite direction from the protein-coding transcript. 
(d) Enhancer, when lncRNA (elncRNA) is located in enhancer regions. (e ) , ( f ) Sense, or 
Antisense, when lncRNA overlapping one or more exons of another transcript on the same, 
or opposite, strand, respectively (Taken from Devaux et al., 2015). 
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1.3.5 Functions and mechanisms 
 
Despite the large number of lncRNAs in mammals, only a relatively small proportion has 
been demonstrated to be biologically relevant. At present, ~295 lncRNAs have been 
functionally annotated in lncRNAdb (a database of literature described LncRNAs), with 183 
in Homo sapiens (lncRNAdb, 2015). LncRNAs are emerging primarily as important 
regulators of gene expression at the transcriptional and post-transcriptional level (Fig.I.8). 
They demonstrate distinctive roles in modulating tissue-specific epigenomic states and 
nuclear organization, which are critical for correct gene regulatory network activity (Cabili 
et al., 2015). Whereas miRNAs are known to downregulate gene expression by inducting 
mRNA degradation (Guo et al., 2010), lncRNAs are mainly known as central regulators of 
chromatin and gene expression by positively or negatively controlling the expression of 
their target protein-coding genes (Geisler & Coller, 2013).  
 
Regarding their modes of transcriptional regulation, it has been shown that lncRNAs could 
work either in cis when their effects are restricted to the chromosome from which they are 
transcribed, thus regulating their immediate genomic neighbours (Derrien et al., 2012; 
Dimitrova et al, 2014; Dimond, 2014; Magistri et al., 2012; Wang et al., 2011) or in trans 
when they affect genes on other chromosomes (Derrien et al., 2012; Peterlin et al., 2012; 
Yakovchuk et al., 2011). Although the function of most lncRNAs remains unknown, it has 
become clear that lncRNAs interact with the nuclear architecture and are involved in divers 
biological processes. LncRNAs can regulate gene expression programs through a variety 
of mechanisms, such as epigenetic modifications of DNA, alternative splicing, post-
transcriptional gene regulation and mRNA stability and translation (Mercer & Mattick, 
2013; Schonrock et al., 2012; Tripathi et al., 2010; Yoon et al., 2012) (Fig.I.9). 
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Based on the current knowledge, our understanding of lncRNA functions remain extremely 
primitive at this time when compared with to the other classes of ncRNAs (Xiao et al., 
2014). 
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Figure I.8: 'Central dogma' in the context of regulatory non-coding RNAs. (Taken 
from Wahlestedt, 2013). 
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Figure I.9: Functions of lncRNAs. LncRNAs can impact genetic output at almost every 
stage of a gene’s life cycle—from epigenetic regulation and chromatin remodelling to 
transcriptional and post transcriptional control to protein metabolism (Taken from 
Schonrock et al., 2012). 
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1.3.6 Y chromosome-linked lncRNAs 
 
There is currently little a nearly literature published regarding lncRNAs on the human Y 
chromosome. As previously mentioned, due to the haploid nature of the Y chromosome, the 
usual methods of analysis such as GWAS cannot be employed to investigate variations, 
resulting in the Y chromosome being routinely excluded from large-scale GWAS or RNA 
sequencing analysis. Currently, only three studies have been published regarding lncRNAs 
on the human Y chromosome: Cabili et al. (2011), Derrien et al. (2012) and Necsulea et 
al. (2014). The most complete human lncRNA annotation to date, produced by the 
GENCODE consortium within the framework of the ENCODE project (GENCODE v7), 
lists 115 lncRNAs that have been found on the human Y chromosome to date, of which 93 
are lincRNAs (List of lncRNAs / Gencode v7 Data Page) (Derrien et al., 2012). However, 
no function or implication in a disease for any of them has been indexed so far (Databases: 
LNCipedia, lncRNAdb, and LncRNADisease). 
 
1.3.7 LncRNAs in diseases 
 
Understanding the lncRNA regulation of transcriptional or post-transcriptional gene 
regulation expands our knowledge of several diseases. Divers associations between 
altered lncRNA function and gene expression have been linked to clinical disease 
phenotypes: Alpha-Thalassaemia (Tufarelli et al., 2003), Alzheimer’s disease (Faghihi et 
al., 2008), Human Spinocerebellar Ataxia Type 8 (Moseley et al., 2006), and Myotonic 
Dystrophies (Ranum et al., 2006). Moreover, lncRNAs are emerging as new players in 
the cancer paradigm demonstrating their potential roles in both oncogenic and tumour 
suppressive pathways in numerous human carcinomas, including those of the breast, 
pancreas, lung, colon, prostate, liver and ovarian cancer (Chung et al., 2011; Guo et al., 
2010; Lai et al., 2012; Lin et al., 2007; Matouk et al., 2007). 
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Many lncRNAs appear to be cardiac-specific, or at least cardiac-enriched (Ounzain et al., 
2015). Studies on both mice and humans showed that these lncRNAs were involved in 
cardiovascular function and disease (Devaux et al., 2015; Iaconetti et al., 2013) (Table 
I.2). Regarding studies on animal model in vitro, it has been shown that the lncRNA 
BraveHeart (also   known   as   AK143260)   may   be   involved   in   pluripotency and 
cardiomyocyte differentiation. In fact, this lncRNA could be involved in specification of the 
cardiac lineage in vitro (Klattenhoff et al., 2013). It has also been found that beta-Myosin 
Heavy Chain (β-MHC) NAT may be involved in cardiac muscle contraction regulation, 
especially in heart contractility (Haddad et al., 2010). Finally, the myosin heavy-chain-
associated RNA transcript (Mhrt) has been recently described as the first example of 
lncRNA that inhibits myopathy and chromatin remodelers in mice (Han et al., 2014). 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table   I . 2: LncRNAs with characterised functions in cardiovascular system.   
M = mitochondrial (Adapted from Devaux et al., 2015). 
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1.3.8 LncRNAs in vascular development and CAD 
 
There is a small number of lncRNAs known to be involved in vascular development and 
disease so far. One of the most well- known is ANRIL, an antisense non-coding RNA 
located on chromosome 9p21, which has previously been associated with CAD risk 
(McPherson et al., 2007). ANRIL is expressed in tissues and cell types that are affected 
by atherosclerosis, such as primary coronary smooth muscle cells, vascular endothelial 
cells, human monocyte-derived macrophage cells (Broadbent et al., 2008). Notably, 
increased expression of ANRIL transcripts was directly correlated with the severity of 
atherosclerosis (Holdt et al., 2010; Schonrock et al., 2012). However, despite the 
potential importance of ANRIL to vascular disease, the pathophysiology underlying the 
link between ANRIL and CAD remains currently unknown.  
 
Another example of a ncRNA correlated with vascular disease is the natural antisense 
transcript sONE, also known as eNOS antisense (NOS3AS). A key function of this 
lncRNA is the regulation of endothelial nitric-oxide synthase (eNOS) expression in a 
post-transcriptional manner under normoxic and hypoxic conditions. Over- expression 
of sONE in endothelial cells reduces eNOS expression. Alterations of nitric-oxide 
production by the vascular endothelium result in endothelial dysfunction, which occurs 
as a prelude to atherosclerosis (Fish et al., 2007). An additional example is the new long 
noncoding antisense transcript tie-1AS. It is required for the regulation of tyrosine kinase 
containing immunoglobulin and epidermal growth factor homology domain-1 gene (tie-
1) levels in vivo and in vitro (Li et al., 2010). Analysis of tie-1AS lncRNA and tie-1 
revealed that the ratio of tie-1 versus tie-1AS lncRNA is opposite in normal placenta 
tissue compared with vascular abnormal tissue. Over-expression of tie-1 AS lncRNAs 
resulted in defects in endothelial cell junctions and tube formation. For the first time 
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these results identified a lncRNA that plays a functional regulatory role with potential 
implications in the control of vascular development. 
 
In summary, the results described above indicate that lncRNAs are involved in different 
aspects of development and disease but their role in the cardiovascular system is under 
current examination. 
 
 
1.4  RELATIONSHIP BETWEEN CAD AND THE LIVER 
 
1.4.1 Insulin resistance and atherosclerosis 
 
The liver is important for the regulation of cholesterol levels in the body. Not only it 
synthetises cholesterol that is exported to other cells, but it also removes cholesterol from 
the body by converting it to bile salts. Furthermore, the liver synthesizes lipoproteins 
involved in transporting cholesterol and lipids throughout the body. Cholesterol 
synthesis in hepatocytes is under negative feedback regulation: increased cholesterol in 
the cell decreases the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, the rate-limiting enzyme in cholesterol synthesis. It has been known that a 
correlation exists between a  fatty liver, also known as hepatic steatosis, and CAD 
(Biddinger & Emanuelli, 2011; Nseir & Assy, 2011; Yusuf et al., 2004). In 1988, Gerald 
Reaven was the first person to show that a complex of metabolic abnormalities, including 
glucose intolerance, hypertriglyceridemia and reduced levels of HDL-cholesterol is present 
in individuals at increased risk for cardiovascular disease (Reaven, 1988). 
However, despite studies showing a positive correlation between increased hepatic free 
fatty acids (FFAs) and atherosclerosis (Nakayama et al., 2011), our understanding regarding 
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this exact mechanism promoting atherosclerosis is still not fully understood. Most notably, 
we need to have a better understanding regarding the relative importance of insulin 
resistance versus hyperglycaemia, and the concept that “insulin resistance” can mean either 
defective insulin receptor signalling or overstimulation of insulin receptor pathways 
caused by hyperinsulinemia (Brown & Goldstein, 2008). The possible mechanisms are 
summarised in Figure I.10. 
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Figure I.10: Possible mechanisms through which insulin resistance in endothelial cells, 
vascular smooth muscle cells, and macrophages promotes atherogenesis. In early/mid-
stage atherosclerotic lesions, insulin resistance is associated with a decrease in 
endothelial nitric oxide synthase ( eNOS) activation and nitric-oxide (NO) production and 
an increase in vascular cell adhesion molecule 1 (VCAM-1) expression by arterial 
endothelial cells. Both of these perturbations may be due to downregulation of the insulin 
receptor-Akt1 pathway in endothelial cells. The net effect is endothelial dysfunction and 
activation, leading to defective vasodilation and increased entry of inflammatory cells into 
the plaque (Taken from Bornfeldt & Tabas, 2011). 
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1.4.2 HepG2: human model liver cells in CAD research 
 
The human hepatocellular liver carcinoma cell line, HepG2, is an immortalised cell line 
which was derived from the liver tissue of a 15-year-old Caucasian American male with 
a well-differentiated hepatocellular carcinoma (HCC). Because of its high degree of 
morphological and functional differentiation in vitro, this cell line is a suitable model to 
study notably the intracellular trafficking and dynamics of lipids in human hepatocytes in 
vitro. Multiple studies have used HepG2 cells to show positive correlations between CAD 
and a high level of FFAs in hepatocytes in vitro (Inoue et al., 2009; Morita et al., 2011; 
Nakayama et al., 2011; Norikura et al., 2010; Poirier et al., 2009; Ricchi et al., 2009). 
Therefore, I used this cell line as human model liver cells for my research on CAD and the 
human Y chromosome. 
 
1.5 PROBLEM STATEMENTS AND AIMS 
It is well known that high levels of FFAs in blood are one of the main causes of CAD. 
Although evidence suggests that CAD is predominantly a male disease, no gene related to 
the Y chromosome and involved in atherosclerosis has been found so far. 
LncRNAs have been classified as a new class of regulatory RNA molecules and are 
involved in a number of physiological and pathophysiological processes including heart 
development, cardiac muscle contraction regulation, and atherosclerosis. The potential 
function of lncRNAs is limited, however evidence suggests that they could regulate the 
expression of neighbouring protein-coding genes. Currently, their mechanisms and function 
in CAD are not fully understood and therefore warrants further investigation. At present, no 
lncRNA expressed by the human Y chromosome have been studied through gene expression 
analysis.  
 
43 
 
In this context, I hypothesised that Y chromosome-linked lncRNAs may regulate pathways 
involved in lipid metabolism and trigger an over accumulation of FFAs in coronary arteries 
contributing to atherosclerosis, the underlying cause of CAD. 
 
The main objective of this thesis was to therefore further investigate the relationship 
between the Y chromosome (Y chr), lncRNA and CAD in light of the deficiencies within 
the literature to better understand the causative molecular mechanisms of CAD 
pathophysiology in men.   
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The specific aims for each of my studies were as follows:  
 
 To identify through gene expression analysis, selected Y chromosome-linked 
lincRNAs in leukocytes using blood from healthy men, and then compare their 
expression across 20 different normal, human tissues (Chapter 2).   
 
 To study the expression of the Y-linked lincRNAs implicated in 
atherosclerosis, and investigate their potential role in this disease using an in 
vitro liver cell model system of atherosclerosis, the human hepatoma cell line, 
HepG2 (Chapter 3).    
 
 To examine the transcriptome of atherosclerotic coronary artery smooth muscle 
cells and to investigate the expression of Y chromosome genes in these diseased 
cells compared to healthy cells (Chapter 4).     
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1.6 JUSTIFICATION OF THE RESEARCH BIOLOGICAL MATERIAL APPROACH 
 
To further our knowledge in regards to the Y chromosome and CAD, it was decided to 
begin this PhD research project using blood samples to study the lncRNA gene expression 
in macrophages between male subjects with and without CAD. While we were waiting to 
get blood samples from patients with CAD, we started to work with blood samples from 
healthy volunteer men (positive controls), and women (negative controls) by studying 
lincRNA relative expressions in leukocytes. This first approach allowed us to set up our 
materials and reagents notably to determine the adequate concentrations (template, primers, 
etc.) and to find the more suitable kits and reagents for studying lncRNA gene expression. 
These experiments are described in Chapter 2.  
 
At this point of my PhD, I was unable to obtain blood samples from patients with CAD to 
work with for reasons beyond my control. Therefore, after studying the literature, we 
decided to work on the human model of liver cells in CAD research, the human hepatoma 
cell line, HepG2. These experiments are described in Chapter 3.  
Later on, we established a collaboration with the cardiologist Dr Mitra Shirazi, from the 
Royal Adelaide Hospital (SA), who provided us with more than 80 blood samples from 
male subjects with and without CAD. Unfortunately, due to the inappropriate storage of 
those after blood collection and knowing that they had been collected from patients between 
2011 and 2013, we could not use them for our experiments as we found that the RNA 
extracted from them was degraded [Note: some of the blood samples were tested with three 
different types of RNA extraction methods using different kits. In the end, similar RNA 
concentrations and qualities were obtained].  
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After the study on the human hepatoma cell line, HepG2, to advance in the CAD 
research, I moved onto primary cell culturing by studying the RNA transcriptome in 
coronary artery vascular smooth muscle cells, diseased (atherosclerotic cells) and non-
diseased (healthy cells). These experiments are described in Chapter 4.   
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2. CHARACTERISATION OF HUMAN Y CHROMOSOME-
LINKED LONG INTERGENIC NON-CODING RNAS 
(LINCRNAS) 
 
2.1 ABSTRACT 
 
Background: Coronary artery disease (CAD) is one of the leading causes of morbidity and 
mortality globally. However, the pathogenesis of CAD is still poorly understood. Previous 
studies have shown that genetic variation within the Y chromosome is associated with an 
increased risk of developing CAD independent of traditional cardiovascular risk factors; 
possibly through a modulating effect of an adaptive immunity and inflammatory response 
by macrophages in men. Long non-coding RNAs (lncRNAs) have recently gained focused 
attention as a new class of regulatory RNA molecules involved in cardiovascular function 
and associated disease, particularly long intergenic non-coding RNAs (lincRNAs), the 
largest class of lncRNA described so far. To date, Y chromosome-linked lincRNAs are 
poorly characterised and the potential link between these RNAs and CAD in men has not 
been investigated. Aims: The aim of this study is to better understand the potential function 
of novel Y-linked lincRNAs in men, especially in white blood cells (WBCs) as an effector 
tissue for CAD. Methods: From the first reference catalogue on human Y chromosome-
linked lincRNAs, primers for nine Y-linked lincRNA transcripts (lnc-KDM5D-4:1, lnc-
ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-
1:1, lnc-RBMY1J-1:2 and lnc-RBMY1J-1:3) were designed using the web-based tool 
Primer-BLAST from the DNA template sequence available on the LNCipedia, the first 
database with annotated human Y-linked lncRNAs [in January 2013]. Then, the lincRNA 
transcripts were analysed by quantitative PCR (qPCR) for differential expression in WBCs 
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from healthy men and in a tissue panel of 20 different normal, human tissues. Results: PCR 
primers for Y-linked lincRNAs were able to be designed from the DNA template sequence, 
and qPCR analysis identified distinct tissue-specific expression profiles. The Y 
chromosome-linked lincRNA transcripts lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-
ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4 and lnc-RBMY1J-1:3 were found to be 
expressed in WBCs in healthy men. Conclusion: This is the first study to use gene 
expression analysis to characterise the expression of Y-linked lincRNAs in humans by 
providing an expression pattern for the Y-linked lincRNA transcripts, lnc-KDM5D-4:1, 
lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-
RBMY1J-1:1, lnc-RBMY1J-1:2 and lnc-RBMY1J-1:3, across 20 human healthy tissues 
and in blood. Finally, the Y-linked lincRNA transcripts lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-
ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, and lnc-RBMY1J-1:3 
should be further studied, especially in WBCs such as macrophages, as they could be 
potential candidates for CAD.    
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2.2 INTRODUCTION 
 
In humans, males die at a greater rate than females during every life stage, except during 
the oldest ages. This comparison leads to the question of why such a difference exists? 
(Charchar et al., 2003). Corrections for risk factors such as diet and hormones still do not 
explain this gap between men and women. Therefore, one of the most obvious places to 
look is in gene differences and RNA expression on the sex chromosomes, in particular the 
Y chromosome (Skaletsky et al., 2003). Previous studies have shown that a genetic 
variation within the human Y chromosome is associated with an increased risk of 
developing CAD independent of traditional cardiovascular risk factors; possibly through a 
modulating effect of an adaptive immunity and inflammatory response by macrophages in 
men (Bloomer et al., 2013; Charchar et al., 2012; Shankar et al., 2007). However, the exact 
cause and the potential Y-linked genes implicated in this process are still to be discovered 
(Bloomer et al., 2013).  
In recent years, lncRNAs have gained focused attention as a new class of regulatory RNA 
molecules involved in cardiovascular function (Klattenhoff et al., 2013) and associated 
disease (Ounzain et al., 2015; Schonrock et al., 2012). It is not known whether these new 
regulatory RNA molecules may play a role in the association between the Y chromosome 
and CAD. To date, lincRNAs - the largest class within the lncRNA group which can be 
found on the human Y chromosome - have only been described through RNA sequencing 
by Cabili et al. (2011) and Derrien et al. (2012). However, the number of lincRNAs found 
on the Y chromosome varies between the two studies, as well as their positions along this 
chromosome. Due to their expression profile not currently being well described, Y 
chromosome-linked lincRNAs need to be further characterised especially in the context of 
CAD. 
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Therefore, in order to gain a better understanding of the potential function of Y-linked 
lincRNAs in CAD in men, the aims of this study are (1) to determine which lincRNAs are 
expressed in male WBCs (leukocytes) as an effector tissue for CAD, and (2) to determine 
their global tissue expression profile across 20 different normal, human tissues. 
2.3 METHODOLOGY 
Section 2.3 and all associated material has been 
removed at the author's request
58 
 
 
 
 
 
 
 
 
  
 
2.4 RESULTS 
2.4.1 Y chromosome-linked lincRNAs: primer validation and optimisation.  
 
After selection of five Y-linked lincRNA genes based on their expression in tissues relevant 
to CAD [such as heart and WBCs] as found by Cabili et al. (2011) using RNA-seq (Table 
II.1), PCR primers were designed using the web-based tool Primer-BLAST from the DNA 
template sequence available on the LNCipedia database. In total, the following nine Y-
linked lincRNA transcripts from five lincRNA genes selected were designed: lnc-KDM5D-
4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-
RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-1:3. For the other transcripts, primers 
not specific to the template were obtained, therefore no primers were selected for those. All 
the primers were validated by PCR in male WBCs (5 biological samples) and in female 
WBCs (2 biological samples). The DNA amplification fragment size was checked by gel 
electrophoresis (data not shown). An amplification was found for all the lincRNA transcripts 
in male WBCs (no amplification was obtained in female WBCs). Then, the concentration 
and the annealing temperature of the primers were optimised by qPCR in WBCs and the 
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melt curve analysis assessed that a single PCR product (also known as amplicon) was 
amplified for each lincRNA transcript studied (data not shown). 
 
2.4.2 The expression of Y-linked lincRNAs in white blood cells (WBCs) and 
in 20 human tissues. 
 
Previously studied through sequencing by Cabili et al. (2011), the following nine Y-
specific lincRNA transcripts, lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, 
lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2 and lnc-
RBMY1J-1:3. were studied for the first time by qPCR in WBCs (leukocytes) from five 
healthy men and two healthy women, and also in a tissue panel of 20 different, normal, 
human tissues. 
 
2.4.2.1 Expression of Y-linked lincRNA transcripts in WBCs. 
qPCR analysis showed that all the lincRNA genes studied were expressed in WBCs 
(leukocytes) in men. However, no expression was found for the following two transcripts 
lnc-RBMY1J-1:1 and lnc-RBMY1J-1:2. A high relative expression was found for lnc-
RBMY1B-1:1 (Relative expression=218.84), lnc-RBMY1B-1:4 (Relative 
expression=197.26), lnc-ZFY-1:1 (Relative expression=173.55), and lnc-ZFY-1:3 
(Relative expression=207.09) in comparison to the other transcripts (Relative expression 
<100) (Fig.II.1-9 & Table II.4). As expected, no expression was found for all the lincRNA 
transcripts studied in female WBCs (negative controls) (data not shown). CT results were 
calculated from 3 independent experiments and normalised with two housekeeping genes 
(HKGs), EEF2 and UBC. Similar patterns of expression change were obtained with both 
sets of genes. [Note: only results from EEF2 are represented here]. 
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2.4.2.2 Expression of Y-linked lincRNA transcripts in human tissues. 
qPCR analysis showed that expression of the lincRNAs were found in all the tissues of the 
panel, except in the cervix and ovary as expected for female tissues. However, an 
expression was found in the maternal placenta for the following transcripts: lnc-ZFY-1:1, 
lnc-ZFY-1:3, lnc-ZFY-2:1 (Table II.4). By studying the expression of lincRNAs per 
tissue, a differential expression between tissues was noticed for all of the lincRNAs 
studied. Overall, tissues from the colon, small intestine and spleen were found to have the 
highest level of lincRNA expression (Table II.4) with all the transcripts studied expressed 
in the testes (Fig.II.1-9). CT results were calculated from 3 independent experiments and 
normalised with two housekeeping genes (HKGs), EEF2 and UBC, with similar patterns 
of expression change obtained with both sets of genes. [Note: only results from EEF2 are 
represented here]. 
 
2.4.2.3 Y-linked lincRNA expression comparison with results from 
Cabili et al. (2011). 
Y-linked lincRNA relative expression patterns were compared to those found in related 
tissues studied by Cabili et al. (2011). These are WBC, adipose, brain, colon, heart, kidney, 
liver, lung, ovary, prostate, skeletal muscle, and testes (Appendix 2.1). Similarities in 
tissue-specific expression were observed, with differences and observations in lincRNA 
expressed by qPCR (not RNA-seq tissue analysis) summarised in Table II.4. [Note: Cabili 
et al. studied the expression of the entire RNA sequence, while this study focused on the 
expression of the different transcripts (if more than one exists) from the lincRNA genes]. 
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Figure II.1: lnc-KDM5D-4:1 expression profile. Relative expression of lnc-KDM5D-4:1 
after qPCR in leukocytes and in 20 different normal, human tissues. No expression was 
found in cervix, ovary and placenta. Expression relative to EEF2. Error bars indicate ± 
SEM; n=3. 
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Figure II.2: lnc-ZFY-1:1 expression profile. Relative expression of lnc-ZFY-1:1 after 
qPCR in leukocytes and in 20 different normal, human tissues. No expression was found in 
cervix, ovary and skeletal muscle. Expression relative to EEF2. Error bars indicate ± SEM; 
n=3. 
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Figure II.3: lnc-ZFY-1:3 expression profile. Relative expression of lnc-ZFY-1:3 after 
qPCR in leukocytes and in 20 different normal, human tissues. No expression was found in 
cervix, and ovary. Expression relative to EEF2. Error bars indicate ± SEM; n=3. 
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Figure II.4: lnc-ZFY-2:1 expression profile. Relative expression of lnc-ZFY-2:1 after 
qPCR in leukocytes and in 20 different normal, human tissues. No expression was found in 
cervix, ovary and skeletal muscle. Expression relative to EEF2. Error bars indicate ± SEM; 
n=3. 
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Figure II.5: lnc-RBMY1B-1:1 expression profile. Relative expression of lnc-RBMY1B-
1:1 after qPCR in leukocytes and in 20 different normal, human tissues. Expression relative 
to EEF2. Error bars indicate ± SEM; n=3. 
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Figure II.6: lnc-RBMY1B-1:4 expression profile. Relative expression of lnc-RBMY1B-
1:4 after qPCR in leukocytes and in 20 different normal, human tissues. Expression relative 
to EEF2. Error bars indicate ± SEM; n=3. 
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Figure II.7: lnc-RBMY1J-1:1 expression profile. Relative expression of lnc-RBMY1J-
1:1 after qPCR in leukocytes and in 20 different normal, human tissues. A low expression 
was found in kidney and testes only. Expression relative to EEF2. Error bars indicate ± 
SEM; n=3. 
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Figure II.8: lnc-RBMY1J-1:2 expression profile. Relative expression of lnc-RBMY1J-
1:2 after qPCR in leukocytes and in 20 different normal, human tissues. A low expression 
was found in kidney and testes only. Expression relative to EEF2. Error bars indicate ± 
SEM; n=3. 
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Figure II.9: lnc-RBMY1J-1:3 expression profile. Relative expression of lnc-RBMY1J-
1:3 after qPCR in leukocytes and in 20 different normal, human tissues. An expression was 
found in leukocytes, kidney and testes only. Expression relative to EEF2. Error bars indicate 
± SEM; n=3. 
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Table II.4: Relative expression data summary for Y-linked lincRNAs, and comparison 
with previous published data from Cabili et al. (2011). Relative expression of lincRNAs 
Similar result as Cabili et al. Not expressed according to Cabili et al. 
Not studied by Cabili et al. Low expression (found not expressed by Cabili et al.) 
Expressed according to Cabili et al. 
Gene Transcript
Leucocytes Adipose Bladder Brain Cervix Colon Esophage Heart Kidney Liver Lung Ovary Placenta Prostate Skeletal muscle Small intestine Spleen Testes Thymus Thyroid Trachea
lnc-KDM5D-4 lnc-KDM5D-4:1 11.68 14.15 11.69 5.87 0 25.23 1.99 54.33 2.72 18.85 3.12 0 0 35.48 0.40 2.25 109.38 11.79 16.91 10.81 12.92
lnc-ZFY-1:1 173.55 21.48 12.30 3.77 0 217.31 11.70 10.48 38.61 7.44 9.61 0 13.45 37.31 0 118.59 84.70 8.79 15.81 57.51 36.56
lnc-ZFY-1:3 207.09 36.63 31.55 11.67 0 145.26 11.64 8.62 50.66 12.43 38.13 0 6.61 16.88 1.07 51.34 48.67 8.71 13.00 20.90 15.01
lnc-ZFY-2 lnc-ZFY-2:1 97.15 25.36 16.52 3.31 0 215.13 11.18 8.57 50.80 4.88 4.63 0 8.87 29.81 0 143.15 79.38 8.38 13.65 51.62 33.66
lnc-RBMY1B-1:1 218.84 0 2.34 0 0 112.80 0 0 1.12 0 0 0 0 1.55 0 18.16 13.88 10.68 8.45 7.59 8.59
lnc-RBMY1B-1:4 197.26 0 0 0 0 113.26 0 0 0.76 0 2.37 0 0 3.48 0 43.99 45.04 22.19 12.26 15.18 17.80
lnc-RBMY1J-1:1 0 0 0 0 0 0 0 0 0.58 0 0 0 0 0 0 0 0 1.62 0 0 0
lnc-RBMY1J-1:2 0 0 0 0 0 0 0 0 2.47 0 0 0 0 0 0 0 0 1.74 0 0 0
lnc-RBMY1J-1:3 6.79 0 0 0 0 0 0 0 0.26 0 0 0 0 0 0 0 0 4.97 0 0 0
lnc-RBMY1B-1
lnc-RBMY1J-1
lnc-ZFY-1
Gene Transcript
Leucocytes Adipose Bladder Brai Cervix Colon Esophage Heart Kidney Liver Lung Ovary Placenta Prostate Skeletal muscle Small intestine Spleen Testes Thymus Thyroid Trachea
lnc-KDM5D-4 lnc-KDM5D-4:1 11.68 14.15 11.69 5.87 0 25.23 1 9 54.33 2.72 18.85 3.12 0 0 35.48 0.40 2.25 109.38 11.79 16.91 10.81 12.92
lnc-ZFY-1:1 173.55 21.48 12.30 3.77 0 217.31 11 70 10.48 38.61 7.44 9.61 0 13.45 37.31 0 118.59 84.70 8.79 15.81 57.51 36.56
lnc-ZFY-1:3 207.09 36.63 31.55 11.67 0 145. 6 1 64 8.62 50.66 12.43 38.13 0 6.61 16.88 1.07 51.34 48.67 8.71 13.00 20.90 15.01
lnc-ZFY-2 lnc-ZFY-2:1 97.15 25.36 16.52 3.31 0 215.13 11 18 8.57 50.80 4.88 4.63 0 8.87 29.81 0 143.15 79.38 8.38 13.65 51.62 33.66
lnc-RBMY1B- :1 218.84 0 2.34 0 0 112.80 0 0 1.12 0 0 0 0 1.55 0 18.16 13.88 10.68 8.45 7.59 8.59
lnc-RBMY1B-1:4 197.26 0 0 0 0 113.26 0 0.76 0 2.37 0 0 3.48 0 43.99 45.04 22.19 12.26 15.18 17.80
lnc-RBMY1J-1:1 0 0 0 0 0 0 0 0.58 0 0 0 0 0 0 0 0 1.62 0 0 0
lnc-RBMY1J-1:2 0 0 0 0 0 0 0 2.47 0 0 0 0 0 0 0 0 1.74 0 0 0
lnc-RBMY1J-1:3 6.79 0 0 0 0 0 0 0.26 0 0 0 0 0 0 0 0 4.97 0 0 0
lnc-RBMY1B-1
lnc-RBMY1J-1
lnc-ZFY-1
Gene Transcript
Leucocytes Adipose Bladder Brain Cervix Colon Esophage Heart Kidney Liver Lung Ovary Placenta Prostate Skeletal muscle Small intestine Spleen Testes Thymus Thyroid Trachea
lnc-KDM5D-4 lnc-KDM5D-4:1 11.68 14.15 11.69 5.87 0 25.23 1.99 54.33 2.72 18.85 3.12 0 0 35.48 0.40 2.25 109.38 11.79 16.91 10.81 12.92
lnc-ZFY-1:1 173.55 21.48 12.30 3.77 0 217.31 11.70 10.48 38.61 7.44 9.61 0 13.45 37.31 0 118.59 84.70 8.79 15.81 57.51 36.56
lnc-ZFY-1:3 207.09 36.63 31.55 11.67 0 145.26 11.64 8.62 50.66 12.43 38.13 0 6.61 16.88 1.07 51.34 48.67 8.71 13.00 20.90 15.01
lnc-ZFY-2 lnc-ZFY-2:1 97.15 25.36 16.52 3.31 0 215.13 11.18 8.57 50.80 4.88 4.63 0 8.87 29.81 0 143.15 79.38 8.38 13.65 51.62 33.66
lnc-RBMY1B-1:1 218.84 0 2.34 0 0 112.80 0 0 1.12 0 0 0 0 1.55 0 18.16 13.88 10.68 8.45 7.59 8.59
lnc-RBMY1B-1:4 197.26 0 0 0 0 113.26 0 0 0.76 0 2.37 0 0 3.48 0 43.99 45.04 22.19 12.26 15.18 17.80
lnc-RBMY1J-1:1 0 0 0 0 0 0 0 0 0.58 0 0 0 0 0 0 0 0 1.62 0 0 0
lnc-RBMY1J-1:2 0 0 0 0 0 0 0 0 2.47 0 0 0 0 0 0 0 0 1.74 0 0 0
lnc-RBMY1J-1:3 6.79 0 0 0 0 0 0 0 0.26 0 0 0 0 0 0 0 0 4.97 0 0 0
lnc-RBMY1B-1
lnc-RBMY1J-1
lnc-ZFY-1
Gene Transcript
Leucocytes Adipose Bladder Brain Cervix Colon Esophage Heart Kidney Liver Lung Ovary Placenta Prost te Skeletal muscle Small intestine Spleen Testes Thymus Thyroid Trach a
lnc-KDM5D-4 lnc-KDM5D-4:1 11.68 14.15 11.69 5.87 0 25.23 1.99 54.33 2.72 18.85 3.12 0 0 35.48 0.40 2.25 109. 8 11.79 16.91 1 .81 12 92
lnc-ZFY-1:1 173.55 21.48 12.30 3.77 0 217.31 11.70 10.48 38.61 7.44 9.61 0 3.45 37.31 0 118.59 84.70 8.79 15.81 57.51 6 56
lnc-ZFY-1:3 207.09 36.63 31.55 11.67 0 145.26 11.64 8.62 50. 6 12.43 38.13 0 6.61 6.88 1.07 51. 4 48.67 8.71 13.00 20.90 5 01
lnc-ZFY-2 lnc-ZFY-2:1 97.15 25.36 16.52 3.31 0 215.13 11.18 8.57 50.80 4.88 4.6 0 8.87 29.81 0 1 3.15 79.38 8.38 13.65 51.62 33 66
lnc-RBMY1B-1:1 218.84 0 2.34 0 0 112.80 0 0 1.12 0 0 0 1.55 0 18.16 13.88 10.68 8.45 7.59 8 9
lnc-RBMY1B-1:4 197.26 0 0 0 0 113.26 0 0 0.76 0 2.37 0 0 3.48 0 43.99 45.04 22.19 12.26 15.18 17 80
lnc-RBMY1J-1:1 0 0 0 0 0 0 0 0 0.58 0 0 0 0 0 0 1.62 0 0
lnc-RBMY1J-1:2 0 0 0 0 0 0 0 0 2.47 0 0 0 0 0 0 1.74 0 0
lnc-RBMY1J-1:3 6.79 0 0 0 0 0 0 0 0.26 0 0 0 0 0 0 4.97 0 0
lnc-RBMY1B-1
lnc-RBMY1J-1
lnc-ZFY-1
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by qPCR in male leukocytes and in 20 different normal human tissues. Results highlight 
novel tissue-specific expression profiles for lincRNAs (green fill) and also compare the 
lincRNA expression previously studied via bioinformatics by Cabili et al. (2011) (Appendix 
2.1); similarities (white fill) and differences (pink and orange fills) are observed by gene 
expression analysis (qPCR). Expression relative to EEF2; n=3. 
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2.5 DISCUSSION 
 
The main aim of this chapter was to determine which Y chromosome-linked lincRNAs may 
be potential candidates for the development of CAD in men. Specifically, this study aimed 
to gain an understanding of the potential function of Y-linked lincRNAs by studying their 
global tissue expression across 21 healthy tissues, including blood. The main findings of 
this part of my thesis are as follows: (1) Y-linked lincRNAs are expressed at low levels with 
a high tissue-specificity for some. (2) The RNA gene lnc-KDM5D-4 is widely expressed 
across the body in men while lnc-RBMY1J-1 gene is specific to the testes. The research 
performed in this chapter was the first study on Y chromosome-linked lincRNAs using gene 
expression analysis (qPCR), and the first to investigate the expression of Y-linked 
lincRNAs through human tissues by providing an expression pattern for nine (unannotated 
in PubMed) Y-linked lincRNA transcripts, lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, 
lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2 
and lnc-RBMY1J-1:3, in men WBCs (leukocytes) and across 20 different normal, human 
tissues.  
 
Previously discovered through sequencing by Cabili et al. (2011), the following Y-linked 
lincRNA transcripts, lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-
RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2 and lnc-RBMY1J-
1:3 were studied for the first time by qPCR gene expression analysis in WBCs and in 20 
healthy tissues such as adipose, bladder, brain, cervix, colon, esophagus, heart, kidney, 
liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, testes, 
thymus, thyroid, and trachea (Section 2.4.2) (Fig.II.1-9). Across all the tissues, qPCR gene 
expression analysis highlighted that the Y-linked lincRNA transcripts studied are 
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expressed at low levels with the lowest CT number equal at 24.5. These results support 
previous finding on lncRNA transcript low expression levels compared to the transcripts 
produced from the protein coding genes (Bassett et al., 2014; Derrien et al., 2012).  
 
Cabili et al. (2011) found that lnc-KDM5D-4 is specific to the heart, while lnc-ZFY-1, lnc-
ZFY-2, lnc-RBMY1B-1, lnc-RBMY1J-1 are specific to leukocytes (Table II.1). In 
comparison to their results, I found that these lincRNAs are expressed in heart and 
leukocytes, respectively, but were not specific to them. In fact, lnc-KDM5D-4:1 was found 
to be expressed by all the tissues studied (except in female tissues such as ovary, cervix 
and placenta) (Fig.II.1), with its highest expression found in spleen (Relative 
expression=109.38) (tissue not studied by Cabili), then in colon (Relative 
expression=25.23) (Table II.4). This last tissue was studied by Cabili using bioinformatics 
but no expression was found for lnc-KDM5D-4:1 or any other transcripts studied. In 
comparison, my results showed that lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-
ZFY-2:1, lnc-RBMY1B-1:1 and lnc-RBMY1B-1:4 were expressed relatively high in the 
colon (Table II.4).   
 
Overall, the differences between Cabili’s findings and my results suggest that RNA-seq 
may be less sensitive than gene expression analysis by qPCR. These differences can also 
be explained by the nature or the number of male and female samples used by Cabili et al. 
(2011). They used 24 human tissues and cell types but no information has been provided 
on the gender of the donors or the number of samples per tissue and cell type studied. 
Therefore, I cannot make a relevant conclusion from the comparison of my results with 
their findings. The fact that they did not find any lincRNA expression in some tissues such 
as adipose, brain, colon, kidney, liver or thyroid while I found some could be simply due 
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to the fact that they studied tissues from female only.  
 
Regarding the lincRNA relative expression found in the placenta, although this is a 
maternal tissue, the expression of the Y-linked lincRNAs such as lnc-ZFY-1 (Fig.II.2-3 & 
Table II.4) and lnc-ZFY-2 (Fig.II.4 & Table II.4) can be explained by the function of the 
placenta itself. During pregnancy, the placenta is the place for multiple exchanges between 
the mother and the foetus, consisting of oxygen, glucose and other nutritional substances, 
even antibodies are transferred through blood between the mother and the foetus. As the 
placenta transfers the foetal blood, the expression of Y-linked genes by the placenta 
suggest that at least one of the three female donors had a baby boy.   
 
Furthermore, by comparing the tissues from only male donors (8 tissues over the 21 studied 
(WBC included), Appendix 2.2) which were adipose, colon, prostate, spleen, testes, 
thyroid, trachea and WBCs, I found that the tissue where lincRNAs have the strongest 
expression is leukocytes whereas the tissue which expresses the largest number of lincRNA 
transcripts is the testes where all the transcripts studied are expressed (Table II.4). Also, 
lnc-KDM5D-4:1 was found to be expressed by all the tissues studied (except in female 
tissues such as ovary, cervix and placenta) (Fig.II.1) suggesting that this lincRNA is 
widely expressed in male tissues. Regarding lnc-RBMY1J-1, results propose that this RNA 
gene is specific to the testes because this is the only tissue where all its transcripts are found 
to be expressed (Fig.II.7-9). 
 
Overall, this study provides a new knowledge about Y chromosome-linked lincRNA 
expression by providing a novel expression profile for nine Y-linked lincRNA transcripts, 
lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-
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RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-1:3 across 20 
human healthy tissues. Furthermore, this study presents the first evidence through gene 
expression analysis that Y chromosome-linked lincRNAs lnc-KDM5D-4:1, lnc-ZFY-1:1, 
lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, and lnc-RBMY1J-1:3 
are expressed in male leukocytes. Therefore, these lincRNAs need to be studied further, 
especially in leukocytes such as macrophages as they could be potential candidates for 
CAD research.    
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3. IDENTIFICATION AND ROLE OF Y CHROMOSOME-
LINKED LINCRNAS INVOLVED IN INCREASED FREE 
FATTY ACID AND INSULIN RESISTANCE IN HEPG2 CELLS.  
 
3.1 ABSTRACT 
 
Background: Coronary artery disease (CAD) is one of the leading causes of morbidity and 
mortality globally. However, the pathogenesis of atherosclerosis which leads to CAD and 
results in heart attacks, heart failure and death is not well understood. In this context, studies 
have demonstrated a positive correlation between increased hepatic free fatty acids (FFAs) 
in atherosclerosis and CAD. Previous studies have shown that genetic variation within the 
Y chromosome is associated with an increased risk of developing CAD. Long non-coding 
RNAs (lncRNAs) have recently gained focused attention as a new class of regulatory RNA 
molecules involved in cardiovascular function and associated disease, however the 
molecular mechanisms implicated in disease-processes are not well defined. Aims: This 
study aims to identify Y-linked long intergenic non-coding RNAs (lincRNAs), the largest 
class of lncRNA described so far, implicated in atherosclerosis and investigate their role in 
this disease using the human hepatoma cell line, HepG2, as an in vitro liver cell model 
system of atherosclerosis. Methods: The expression of the Y-linked lincRNA transcripts 
lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-
RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-1:3 was studied by 
quantitative PCR (qPCR) in HepG2 cells. To create an FFA-induced steatosis model, 
HepG2 cells were treated with 0.3 mM of the FFA palmitate for 24 hours and qPCR was 
performed on the lincRNA transcripts. To determine the subcellular localisation of selected 
lincRNAs, an RNA fluorescence in situ hybridisation (FISH) was conducted. Finally, to 
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elucidate the biological role of selected lincRNA in the context of atherosclerosis, a knock-
down experiment in HepG2 cells using antisense oligonucleotides (GapmeRs) was 
performed, followed by the atherosclerosis RT2 Profiler PCR Array gene expression 
analysis. Results: in HepG2 cells treated with palmitate for 24h, qPCR analysis determined 
a significant increase in the expression of the Y-linked lincRNA lnc-KDM5D-4 (1519 bp 
length). RNA FISH revealed that this lincRNA is a nuclear-retained Y-specific lincRNA. 
The atherosclerosis RT2 Profiler PCR Array profiling the expression of 84 coding-genes 
related to atherosclerosis showed that silencing lnc-KDM5D-4 in HepG2 cells resulted 
mainly in a significant dysregulation of the anti-apoptotic genes BIRC3 (baculoviral IAP 
repeat containing 3), IL1A (interleukin 1 alpha), BCL2 (BCL2, apoptosis regulator), and TNF 
(tumor necrosis factor). Conclusion: lnc-KDM5D-4 is a Y-linked nuclear-retained 
lincRNA in human hepatocytes, also it is upregulated in palmitate-induced steatosis within 
these cells and may regulate the inhibitor of apoptosis (IAP) genes, especially BIRC3, a 
protein-coding gene involved in the pathology of atherosclerosis. Overall, this is the first 
study on a Y chromosome lincRNA and also the first to show any subcellular localisation 
and potential function for a Y-linked lincRNA in modulating CAD using HepG2 cells. 
 
 
 
 
 
 
 
 
 
80 
 
3.2 INTRODUCTION 
 
The human Y chromosome is associated with circulating cholesterol levels (Charchar et al., 
2004) and an increased risk of developing CAD in men (Charchar et al., 2012), hence, there 
is a need to investigate the cause and effect relationships between this chromosome and 
cardiovascular phenotypes in men. In recent years, lncRNAs have gained focused attention 
as a new class of regulatory RNA molecules involved in cardiovascular function 
(Klattenhoff et al., 2013) and associated disease (Ounzain et al., 2015; Schonrock et al., 
2012). Also, a correlation has already been made between familial hypercholesterolemia 
and lncRNAs (Ahmed et al., 2013). Using the human hepatoma cell line, HepG2 as an 
in vitro liver cell model system of atherosclerosis to study CAD (Inoue et al., 2009; Morita 
et al., 2011; Nakayama et al., 2011; Norikura et al., 2010; Poirier et al., 2009; Ricchi et al., 
2009), this study aims (1) to identify the Y-linked lincRNAs expressed in HepG2 cells, (2) 
to study and compare their expression in atherosclerosis physiologic context, and (3) to 
elucidate their potential role in this disease.  
 
The liver synthesizes cholesterol and lipoproteins involved in cholesterol transport 
throughout the body, thus making it the central place for the regulation of cholesterol levels. 
It is also known that a correlation exists between non-alcoholic steatosis, characterised by 
an abnormal accumulation of hepatic FFAs, and CAD (Bradbury, 2006; Nakayama et al., 
2011). Furthermore, elevated levels of FFAs are thought to contribute to the induction of 
insulin resistance and diabetes by modifying glucose and lipid metabolism, as well as 
inflammatory cascades in liver (De Luca & Olefsky, 2006; Unger, 2003). Although several 
studies strongly suggest that hepatic lipid accumulation causes hepatic insulin resistance, 
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the molecular mechanisms responsible for this relationship remain uncertain (Bornfeldt & 
Tabas, 2011). 
Therefore, in the present study, I hypothesised that Y-linked lncRNAs may regulate 
pathways involved in lipid metabolism in the liver and trigger an over accumulation of 
FFAs in coronary arteries contributing to atherosclerosis; the underlying cause of CAD. 
Because the expression of Y-linked lincRNAs in HepG2 cells was still undiscovered, my 
first step to verify my hypothesis was to identify the Y-specific lincRNAs [lincRNA 
selected in my first study in Chapter 2] in HepG2 cells through gene expression analysis 
and compare the expression results with those previously found in (normal) liver tissue in 
Chapter 2. Then, the expression of lincRNAs was studied in a fatty liver context by 
triggering separately, an intracellular increase in the concentration of the FFA palmitate, 
and insulin resistance in HepG2 cells.  
 
From these findings, the Y-linked lincRNA, lnc-KDM5D-4 was therefore chosen as the 
focus in the study. The RNA in situ hybridisation (RNA FISH) was performed to localise 
lnc-KDM5D-4 within the cell. To date, lncRNAs from the Y chromosome remain 
uncharacterised, therefore basic properties such as subcellular localisation or absolute 
abundance in single cells remain unknown. Knowledge of lncRNA subcellular localisation 
patterns can provide fundamental insights into their biology and foster hypotheses for 
potential molecular roles (Brown et al., 1992; Clemson et al., 1996; Maamar et al., 2013). 
For instance, an exclusively nuclear localisation would argue against putative lncRNAs 
encoding short peptide sequences, because translation occurs in the cytoplasm.  
 
Finally, to further study the biology and functions of lnc-KDM5D-4, a lncRNA knock-down 
was carried out using specific antisense oligonucleotides (AOs) followed by a gene 
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expression analysis using a RT2 Profiler PCR Array. In fact, siRNA approaches to knock-
down lncRNA have been met with limited success, however the use of AOs appears to be 
a new strategy to study lncRNA function. 
3.3 METHODOLOGY 
Section 3.3 and all associated material has been 
removed at the author's request
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3.4 RESULTS 
 
3.4.1 The differential expression of Y chromosome-linked lincRNAs in 
HepG2 cells.  
 
To identify and investigate the role of Y chromosome lincRNAs in a fatty liver 
context, the expression of the 9 lincRNA transcripts of interest (previously studied in 
Chapters 2) (Table II.2) were studied by qPCR in the human hepatoma cell line, HepG2 
used as human model liver cells in CAD research.  
The lncRNA HULC (Hepatocellular carcinoma up-regulated long non-coding RNA) was 
used as positive control lncRNA gene in this experiment as HULC is known to be highly 
upregulated in HCC (Panzitt et al., 2007). 
 
qPCR analysis showed that HULC was very high expressed in HepG2 cells, as expected 
(average CT = 19.5) compared to lincRNA expression, and that the following five lncRNA 
transcripts, lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, and lnc-
RBMY1B-1:4, were found to be expressed in HepG2 cells (Fig.III.1); with the average CT 
observed after 3 independent experiments (n=3): 27.0, 27.5, 28.5, 28.3, 28.5, respectively. 
No expression was found for the transcripts lnc-ZFY-1:3, lnc-RBMY1J-1:1, lnc-RBMY1J-
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1:2, and lnc-RBMY1J-1:3 (CT >35). CT results were normalised with HKGs, ACTB and 
UBC, with similar patterns of expression change obtained with both sets of genes. [Note: 
only results from ACTB are represented here]. 
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Figure III.1: Transcripts expression of HULC and Y-linked lincRNAs in HepG2 cells. 
Results of qPCR lincRNA relative expression in untreated HepG2 cells. Expression relative 
to ACTB. Error bars indicate ± SEM; n=3.  
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3.4.2 The effects of palmitate on the transcript expression of Y chromosome-
linked lincRNAs in a steatosis HepG2 cell line. 
 
Positive correlations between CAD and high levels of FFAs, such as the palmitate (Ricchi 
et al., 2009), in hepatocytes in vitro have been previously demonstrated using HepG2 cells 
as a human model liver cells in CAD research (Inoue et al., 2009; Morita et al., 2011; 
Nakayama et al., 2011; Norikura et al., 2010; Poirier et al., 2009). To create a FFA-induced 
steatosis liver cell line, HepG2 cells were stimulated with 0.3mM of palmitate and/or with 
the vehicle (chloroform) for 24 hours to induce lipid accumulation into the cells following 
the manufacturer’s protocol (see Material & Methods). The ORO assay was performed to 
validate the intracellular lipid accumulation after palmitate treatment. Two methods were 
used to assess the results: examination of the intracellular distribution of lipid droplets by 
microscopy (Fig. III.2 A-B), and quantification of the lipid accumulation by absorbance 
measurement (Fig. III.2 C-D). 
After 24h of treatment with palmitate, microscopy results show a clear increase of ORO 
stained lipid droplets (red) in the peri-nuclear region of the cells (Fig. III.2 B) in 
comparison to the control cells (Fig. III.2 A). These results were confirmed by absorbance 
measurement of the lipid quantification (Fig. III.2 D) suggesting that the cells had obtained 
the palmitate-induced steatosis phenotype (significance: p=0.024). 
 The chloroquine treatment for 72h on HepG2 cells, which was used as the positive control 
in the ORO, showed a significant (p=0.035) increase of lipid accumulation into the cells 
treated with chloroquine compared to the control cells (Fig. III.2 C).   
To investigate the potential effect of elevated FFA levels on the expression of the Y-linked 
lincRNAs in the FFA-induced steatosis cells, a qPCR was performed on cells treated with 
palmitate for 24h and cells treated with the vehicle only.  
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qPCR analysis of the lincRNAs showed that addition of palmitate during 24h of treatment 
in HepG2 cells triggered a significant increase (Fold Change =2.16; p-value =0.00216) in 
the expression of lnc-KDM5D-4:1 (Fig. III.3). No significant increase in the expression 
for lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4 and HULC was 
observed (Fold change: <2; p-value >0.05). CT results were normalised with the two HKGs, 
ACTB and UBC, and the same results were obtained with both. [Note: only results from 
ACTB are represented here]. 
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Figure III.2: Assessment of lipid accumulation in HepG2 cells by Oil Red O.  
A-B: Microscopy results of the intracellular distribution of lipid droplets stained in red by 
the Oil Red O solution after 24h of treatment with either the vehicle (chloroform) (A), or 
with the FFA palmitate (0.3mM) (B). C-D: Quantification of the lipid accumulation by 
absorbance measurement after 24h of treatment. Chloroquine treatment (25µM) was used 
as the Oil Red O assay’s positive control (C); cells treated with the FFA palmitate (D). 
Error bars indicate ±SD calculated from sextuplicate wells. NT = no treatment. 
A B 
HepG2 (control) 
100 µm 
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100 µm 
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Figure III.3: qPCR analysis of the Y-linked lincRNA transcript expression in 
palmitate-induced steatosis HepG2 cells. The addition of the FFA palmitate for 24h 
triggers a significant increase (Fold Change =2.16; p-value =0.00216) in the expression of 
lnc-KDM5D-4:1 in HepG2 cells in comparison to cells not treated with palmitate (control 
cells). No significant increase in the expression was found for the transcripts lnc-ZFY-1:1, 
100 
lnc-ZFY-2.1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4 and HULC. Expression relative to 
ACTB. Error bars indicate ±SD; n=4. Student’s t-test: **: p<0.01; ns (not significant): 
p>0.05. 
Section 3.4.3 and all associated material has been removed 
at the author's request
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3.4.4 The effects of insulin on the transcript expression of Y chromosome- 
linked lincRNAs in an insulin-resistant HepG2 cell line. 
To investigate the correlation between steatosis and insulin-resistance as previously 
hypothesised by Brown & Goldstein (2008), and Bornfeldt & Tabas, (2011), the potential 
effect of insulin resistance on the expression of these lincRNAs was studied. To create an 
insulin-resistant HepG2 cell line, cells were stimulated with 10nM of insulin solution over 
0, 0.25, 0.5, 2, 4, 8, 24, and 48 h replacing the media and insulin every 8h. Total cellular 
protein was extracted using RIPA buffer and 20µg of total cellular protein was subjected 
to SDS-PAGE, and subsequently blotted onto Immobilon-PVDF membrane. The relative 
levels of pAkt or pIR were detected relative to total Akt and total IR respectively 
(Fig.III.5). 
Western blot results showed that following 30 min of insulin treatment there was an 
increase in the levels of pAkt that were further increased at 2 and 4h of insulin treatment, 
as similarly for pIR. The level of phosphorylation then rapidly decreased at 8h and became 
almost undetectable at 24 and 48h (Fig.III.5 A). The level of phosphorylation of the IR 
decreased from 24h. Overall, there was no change in total Akt and IR proteins observed, 
suggesting that the cells had obtained the insulin-resultant phenotype. To determine if any 
of the lincRNAs studied responded to insulin-resistance, their expression was analysed by 
qPCR. Results showed no significant changes in the expression of any lincRNAs studied 
in cells stimulated with insulin for 24h (Fig.III.5 B). CT results were normalised with two 
HKGs, ACTB and UBC, and the same results were obtained with both. [Note: only results 
from ACTB are represented here]. 
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Figure III.5: Assessment and effect of insulin-resistance on the Y-linked lincRNA 
expression in HepG2 cells. 
A: Western blot analysis of pAkt, total Akt, pIR and total IR. Antibodies were used to 
immunodetect the levels of pAkt, total Akt, pIR and total IR in an increasingly insulin-
resistance human hepatoma cell line, HepG2. For protein phosphorylation detection, 
10nM insulin was added for 30 min before cell lysates harvest at the indicated time. 
A 
ns 
B 
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Western blot was performed on two independent experiments. 
B: qPCR results of the 24h insulin-stimulated HepG2 cells with no significant changes in 
the expression of lincRNAs in comparison to the cells no treated (control). Expression 
relative to ACTB. Error bars indicate ±SD; n=4. Student’s t-test: ns (not significant): 
p>0.05. 
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3.4.5 Subcellular localisation of the lncRNA transcript lnc-KDM5D-4:1 in 
HepG2 cells. 
Based on my previous results with Palmitate (Section 3.4.2), lnc-KDM5D-4 was specifically 
chosen as its subcellular localisation was not characterised. The aim of the experiment was 
to get insight into its potential function in hepatocytes. For that, the subcellular localisation 
of this lincRNA was explored using RNA FISH (QuantiGene® ViewRNA) to localise 
lncRNA transcripts within the hepatocytes. 
Firstly, the assay was performed without addition of glacial acetic acid (AA) to the fixation 
solution by following the manufacturer’s protocol. This way, although significant 
cytoplasmic signals were observed with the ACTB probe (green) used as a housekeeping 
gene and positive control for the RNA FISH assay (Fig.III.6 C), any signal obtained was 
the results of the lnc-KDM5D-4:1 probe (red) as shown in Fig.III.6 E. After getting these 
negative results, I contacted the Affymetrix specialists. Based on my results, they told me 
that the protocol they provide may not be efficient for nuclear-retained RNAs. If it is the 
case, the results suggest that this lincRNA is localised only in the nucleus. To get nuclear 
signals, I followed Affymetrix specialists’ advice about the permeabilisation procedure of 
the cells during the assay and I also did some literature searching on RNA FISH and nuclear 
targets. The permeabilisation procedure was then amended and glacial AA was added to the 
fixation solution to detect nuclear RNAs. Three different concentrations of AA (0.5%, 1% 
and 2%) were tested as recommended by Battich et al. (2013). From these results, 1% AA 
concentration was determined to be the optimal concentration for use on hepatocytes. This 
concentration was also determined by Battich et al. (2013) to be the most optimal with use 
on another human cell model. An increased amount of false positive signals for lnc-
KDM5D-4:1 with 2% of AA were observed. In contrast, weak signals were observed with 
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0.5% AA for the same probe [data not shown]. By adding 1% of AA into the fixation 
solution, the fluorescence (red) of single-RNA molecule of lnc-KDM5D-4:1 displays a 
strictly nuclear distribution (Fig.III.6 G&F). Furthermore, the single cell 3D movie of this 
result allows us to see better the nuclear distribution; the red signals are located within the 
nucleus stained in blue (DAPI), and no red signal are observed outside of this blue staining. 
The ACTB RNA FISH results (Fig.III.6 C&D) confirm the efficiency of reagents and 
methods used for this assay. As negative controls, wells with only secondary probes were 
tested and no signal displays were seen, as expected, (Fig.III.6 A&B) confirming that 
signals obtained for ACTB and lnc-KDM5D-4:1 are relevant and not due to the mere 
expression of the secondary probes. The results represent 3 independent experiments. [Note: 
the slight difference of green fluorescence between images C and D is due to a microscope 
setting improvement, not to an amendment of the RNA FISH protocol or to a change in 
probe concentration]. RNA FISH results were then confirmed by qPCR using nuclear and 
cytoplasmic RNAs, separately isolated from HepG2 cells, as shown in Figure III.7 
(Spectrophotometer ratios available in Appendix 3.5). 
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>The video of the cell in 3D can be viewed through the link provided:  
https://goo.gl/photos/QgLRauZnJbe73ky37 
 
 
Figure III.6: RNA fluorescence in situ hybridisation analysis of lnc-KDM5D-4:1 in 
HepG2 cells. 
A, B) Cells without probes (negative control). C, D) ACTB-FISH (green) used as 
housekeeping gene and positive control for the RNA FISH assay. F, G, H) RNA FISH 
shows the nuclear localisation of lnc-KDM5D-4:1 RNA (red). Each probe was tested with 
(B, D, F, G, H) or without (A, C, E) addition of acetic acid (AA) at the cell fixation step. 
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This resulted in no observable nuclear signal for lnc-KDM5D-4:1 when AA is not added 
to the fixation solution (E). The permeabilisation procedure was amended and glacial AA 
(1%) was added to the fixation solution to detect nuclear RNAs. Images represent 3 
independent experiments. Confocal microscope magnification: 60x.   
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Figure III.7: Nuclear lnc-KDM5D-4:1 relative expression in HepG2 cells. qPCR lnc-
KDM5D-4:1 transcript expression results from nuclear and cytoplasmic RNAs isolated 
separately from HepG2 cells before reverse transcription, then qPCR. Results show a 
nuclear expression, exclusively, of lnc-KDM5D-4:1 in comparison to ACTB which is 
approximately half nuclear and half cytoplasmic. 
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3.4.6 The effects of lnc-KDM5D-4 knock-down on 84 atherosclerotic genes in 
HepG2 cells. 
 
To elucidate the biological role of Y-linked lnc-KDM5D-4 in the context of 
atherosclerosis, a knock-down using AOs (GapmeRs) that blocked lnc-KDM5D-4:1 
activity was performed followed by a gene expression analysis using the atherosclerosis 
RT2 Profiler PCR Array.  
HepG2 cells were transfected with GapmeRs targeting lnc-KDM5D-4:1 (three different 
probes, lnc-KDM5D-4_I, lnc-KDM5D-4_II and lnc-KDM5D-4_VI respectively, tested 
separately, targeting three different sites) or random scrambled sequence (Negative control 
A GapmeR) which contains no known homology to the mouse, rat or human genome. Cells 
without transfection (Untreated) were also used to check the scramble (negative control 
probe) non-specificity. Accordingly, cells were transfected with GapmeRs targeting lnc-
KDM5D-4:1 or the scramble, and cells were harvested 48h post transfection for qPCR 
analysis. AO-mediated silencing of lnc-KDM5D-4 was assessed using the 2-ΔΔCT method 
to determine relative gene expression from qPCR data normalised with ACTB (Fig.III.8). 
Results showed that the highest knock-down efficiency is obtained when the cells were 
treated with 10nM of the lnc-KDM5D-4_I GapmeR with transcript reduction by 88% (Fold 
change =0.12; p=0.0008). Also, comparison of transfected cells with GapmeRs and 
Scramble to Untreated samples (negative control) suggest that there is no significant 
(p=0.5368) effect of transfection reagent or transfection reagent plus GapmeR respectively, 
on the cell.  
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Figure III.8: Lnc-KDM5D-4 knock-down assessment in HepG2 cells. Cells were 
transfected with GapmeRs targeting lnc-KDM5D-4:1 RNA or random scrambled 
sequence. Cells were harvested 48h post transfection and assayed for lnc-KDM5D-4:1 by 
qPCR with ACTB as HKG. The cells demonstrate AO knock-down of lnc-KDM5D-4 with 
the 3 different tested GapmeRs exhibiting a highest knock-down efficiency with the lnc-
KDM5D-4_I GapmeR with transcript reduction by 88% (Fold change =0.12; p=0.0008). 
Comparison of transfected cells with GapmeRs and Scramble to Untreated samples 
(negative control) show that there is no significant effect of transfection reagent or 
transfection reagent plus GapmeR respectively, on the cell. Error bars indicate ±SD; n=3. 
Statistical significance: * p<0.05, ** p<0.01, *** p<0.001 compared to the Scramble 
group; NS (not significant): p>0.05. 
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After confirmation of the lnc-KDM5D-4 knock-down, the potential transcriptional activity 
of neighbouring genes by lnc-KDM5D-4 (Fig.III.4) was examined through qPCR in 
HepG2 cells with lnc-KDM5D-4 knock-down compared to controls. There were no 
changes in the expression of neighbouring Y chromosome protein-coding genes BPY2, 
DAZ1, DAZ2, PRY2, RBMY1F, RBMY1J and PRY in transfected cells compared to the un-
transfected cells (CT >35 or undetermined) (histogram not shown). 
 
Then, after confirmation of the lnc-KDM5D-4 knock-down in HepG2 cells, an 
atherosclerosis RT2 Profiler PCR Array was performed comparing cells transfected with 
the lnc-KDM5D-4_I GapmeR (n=3; named “Group 1”) and cells transfected with the 
control GapmeR (n=3; named “Control Group”). The human atherosclerosis PCR array 
profiled the expression of 84 genes related to atherosclerosis. Data analysis using the ∆∆CT 
method was made online through the PCR Array Data Analysis Web portal at: 
www.SABiosciences.com/pcrarraydataanalysis.php [Note: Figures III.9 A&B from the 
RT2 PCR array results have been generated automatically by the online software]. Results 
show that reduced lnc-KDM5D4:1 transcript level in HepG2 cells was associated with 
changes in genes implicated in atherosclerosis. A significant increase in the expression of 
9 genes including BIRC3 (baculoviral IAP repeat containing 3), EGR1 (early growth 
response 1), MMP3 (matrix metallopeptidase 3), IL1A (interleukin 1 alpha), BCL2 (BCL2, 
apoptosis regulator), SERPINE1 (serpin family E member 1), VEGFA (vascular endothelial 
growth factor A), PLIN2 (perilipin 2), ITGA2 (integrin subunit alpha 2), and, also, a 
significant decrease in the expression of 2 genes ITGA5 (integrin subunit alpha 5), and TNF 
(tumor necrosis factor) were observed in transfected cells compared to the untransfected 
cells (Fig.III.9 A&B). A comparison between dis-regulated genes and enzymatic pathways 
of atherosclerosis involved (Appendix 3.6) was also summarized in Figure III.10. Results 
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highlight the anti-apoptosis pathway as the main pathway dysregulated. 
Finally, GIANT, the new human tissue-specific network webserver (Greene et al., 2015) 
was used to highlight the potential tissue-specific functional interactions of BIRC3, the most 
dysregulated gene according to the PCR array results (Fold Regulation =12.45, 
p=0.000025) with other protein-coding genes in hepatocytes. According to the functional 
network, generated results predict that BIRC3 interacts with the following protein-coding 
genes: LIF, BPGM, ENSA, STX7, CRYM, GLO1, and ETHE1 in hepatocytes (Fig.III.11). 
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Fig.III.9. A 
Lnc-KDM5D-4_I GapmeR vs. Scramble 
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Fig.III.9. B 
Figure III.9: Atherosclerosis PCR Array gene expression changes. A Human 
Atherosclerosis RT2 Profiler™ PCR Array was utilised to profile the expression of 84 
genes involved in the regulation and enzymatic pathways of atherosclerosis between 
HepG2 cells transfected with GapmeR targeting lnc-KDM5D-4 and scrambled cells. 
A: Results determine that 9 genes were significantly (p<0.05) over-expressed (Fold 
Lnc-KDM5D-4_I  vs. Scramble 
Log2(Fold Change: lnc-KDM5D-4_I vs. Scramble) 
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Regulation >2) (red; top table), and 2 genes were significantly (p<0.05) under-expressed 
(Fold Regulation <2) (green; bottom table) in transfected cells compared to untransfected 
cells. 
B: The volcano plot combines a p-value statistical test with the fold change regulation 
change enabling identification of genes with both large and small expression changes that 
are statistically significant are represented; upregulated genes (red), downregulated genes 
(green) and unchanged genes (black). Relative expression levels of these genes were 
normalised to a set of housekeeping genes (Appendix 3.7). Three independent biological 
samples were used. 
[Figures generated automatically by the Qiagen Web portal software]. 
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Figure III.10: Atherosclerosis PCR Array significant dysregulated genes and 
pathways associated. A Human Atherosclerosis RT2 Profiler™ PCR Array was utilised 
to profile the expression of 84 genes involved in the regulation and enzymatic pathways of 
atherosclerosis between HepG2 cells transfected with GapmeR targeting lnc-KDM5D-4 
and scrambled cells. The significant dysregulated genes are summarised here with their 
pathways associated. Relative levels of these genes were normalized to a set of 
housekeeping genes. Statistical significance: * p<0.05, ** p<0.01, *** p<0.001. 
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Figure III.11: BIRC3 functional predicted interaction partners’ network in human 
hepatocytes. This network was generated using GIANT (Genome-scale Integrated Analysis 
of gene Networks in Tissues) webserver (http://giant.princeton.edu/) and represents the 
predicted protein-coding genes most tightly connected to BIRC3 in human hepatocytes. Edge 
thickness correspond to edge strength (Full name of genes and average edge score number 
in Appendix 3.8). 
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3.5 DISCUSSION 
The main aim of this chapter was to identify and investigate the potential function of 
selected Y-linked lincRNAs in a fatty liver context (steatosis) using the human hepatoma 
cell line, HepG2, as an in vitro liver cell model system of steatosis-associated 
atherosclerosis. The main findings of this part of my thesis are as follows: the Y-linked 
lincRNAs lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, and lnc-
RBMY1B-1:4 are expressed in HepG2 cells, hence in HCC; and lnc-KDM5D-4:1 is a 
nuclear-retained lincRNA in human liver cells, is upregulated in palmitate-induced 
steatosis within hepatocytes, and may regulate the IAP gene BIRC3, a well-described 
protein-coding gene involved in the pathology of atherosclerosis and also in cancer 
progression, as well as PLIN2 gene known to be implicated in lipid metabolism. The 
research performed in this chapter was the first study on a Y chromosome lincRNA, and 
the first to show any subcellular localisation and potential function for a Y chromosome-
linked lincRNA. 
Novel Y chromosome-linked lincRNAs expressed in HepG2 cells. 
Previously studied through sequencing by Cabili et al. (2011), the following Y-specific 
lincRNA transcripts lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1 and 
lnc-RBMY1B-1:4 have been identified for the first time by qPCR gene expression analysis 
in the human hepatoma cell line, HepG2 (see Section 3.4.1). 
In comparison with the lincRNA expression profile results from the findings discussed in 
Chapter 2 (Section 2.4.2), the results here showed a difference in the expression between 
liver (healthy) tissue and HepG2 cells (Fig.III.1). In fact, lnc-ZFY-1:3 was found to be 
expressed in the liver tissue while it was not in HepG2 cells, and no expression was found 
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for lnc-RBMY1B-1 in the liver while both of its transcripts were found to be expressed in 
HepG2 cells. Furthermore, a relative difference level of expression regarding the other 
lincRNAs was observed. This difference of expression can be due to several reasons. The 
first being that the liver tissue is composed of 80% hepatocytes, and 20% cholangiocytes, 
endothelial cells, macrophages, stellate cells, hepatic lymphocytes and hepatic oval cells. 
For its part, the HepG2 cells are composed of hepatocytes, only. The second is the nature 
of the cells itself. As demonstrated by Wilkening et al. (2003), with HepG2 cells being 
immortalised cells, their bio properties differ from the non-cancer hepatocytes. 
Concomitantly, lncRNAs have been found to play critical roles in cancer (Augoff et al., 
2012; Grote et al., 2013; Zhang et al., 2012) especially in HCC as reviewed by He et al. 
(2014) and Liu et al. (2015), so these results make sense. Despite this, no Y chromosome-
linked lncRNA implicated in cancer has been found to date, therefore, a relevant conclusion 
cannot be drawn based on the difference of expression between both samples. 
Recent extensive research analyses have been carried out on lncRNAs and HCC (Fang et 
al., 2014; Zhu et al., 2014). However, there is still lack of information regarding Y 
chromosome-linked lncRNAs in hepatocarcinoma and also in globally in science. This is 
due to the Y chromosome generally being excluded from genome analysis; as seen in 
research studies into the identification and the functions of lincRNAs in mammals that have 
been published in the journal “Nature” (Guttman et al., 2009 & 2011). 
Therefore, this study provides novel evidence of the expression of Y-linked lincRNAs lnc-
KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1 and lnc-RBMY1B-1:4 in 
HCC. Further research focusing on comparing the expression of these Y-linked lincRNAs 
between primary human hepatocytes and the human hepatoma cell line HepG2 should be 
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done as these lincRNAs may play a crucial role in HCC and could be novel potential 
biomarkers for the diagnosis of this cancer in men. 
Regulation of the Y-specific lincRNA lnc-KDM5D-4 in response to palmitate-
induced steatosis in HepG2 cells. 
The human hepatoma cell line, HepG2, was used as a model system to study the 
steatosis-associated atherosclerosis. The expression of 9 Y-linked lincRNAs was studied 
after 24h of palmitate treatment. The palmitate-induced intracellular lipid accumulation 
was validated by the ORO staining assay, confirming that the cells had obtained the 
steatosis phenotype (Fig.III.2). In addition, the lincRNA transcript expression was studied 
by qPCR between steatosis phenotype cells and cells not treated with palmitate, 
demonstrating a significant increase in the expression of lnc-KDM5D-4:1 in cells treated 
with the palmitate.  
These results provide the first evidence for the upregulation of the Y-linked lincRNA, 
known as lnc-KDM5D-4:1 (LNCipedia.org v3.1), in response to palmitate treatment in 
HepG2 cells (Section 3.4.2). Given the role of FFAs in the pathogenesis of CAD, these 
results suggest that the lincRNA gene lnc-KDM5D-4 may play a role in regulating the 
metabolic processes of the liver implicated in atherosclerosis, and thus predominately 
increasing the risk of CAD in men. 
Furthermore, the fact that lnc-KDM5D-4 is not differentially expressed in insulin-
resistance HepG2 cell experiments (Section 3.4.4) demonstrate that the results found with 
the steatosis cell model are independent of those found in the insulin-resistance cells. These 
results confirm that the significant differentiation expression of lnc-KDM5D-4 after the 
FFA-palmitate treatment was triggered by the steatosis phenotype, and not by the insulin-
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resistance phenotype. Lnc-KDM5D-4 is then implicated in hepatic steatosis which can 
occur independently of insulin resistance in the liver as demonstrated by Benhamed et al. 
(2012) and Kato et al. (2015). Whether aberrant expression of this lincRNA plays an 
insignificant role in this context or if it is a mere consequence of disease pathology remains 
an open question. 
Further research on lnc-KDM5D-4 should be done to study the role of this Y-linked 
lincRNA in insulin-resistance and steatosis-associated atherosclerosis. 
Lnc-KDM5D-4, a nuclear-retained Y-specific lincRNA which may act in trans 
and regulate IAP genes involved in atherosclerosis within the liver. 
So far, the main function assigned to lncRNAs has been as regulators of gene expression 
(Geisler & Coller, 2013). To foster a hypothesis for potential molecular roles of lnc-
KDM5D-4, a method using a single molecule RNA FISH was performed to determine its 
subcellular localisation in HepG2 cells (Section 3.4.5). Firstly, regarding the method used, 
the results demonstrated that the addition of 1% of AA into the fixation solution allowed 
us to visualise the lnc-KDM5D-4:1 transcripts located within the nucleus (Fig.III.6 F) as 
no fluorescence signal was obtained without the addition of AA (Fig.III.6 E). Overall, 
these results suggest that lnc-KDM5D-4:1 is a nuclear-retained lincRNA. Results using 
ACTB (Fig.III.6 C&D) confirm the efficiency of reagents and methods used in this assay, 
and notably confirm that the addition of AA does not influence the cytoplasmic RNA 
signal. For negative controls, wells with only the presence of the secondary probes were 
tested and no signal displays were shown, as expected (Fig.III.6 A&B), confirming that 
the signals obtained for ACTB and lnc-KDM5D-4:1 were relevant and not identified as the 
cause of a potential fluorescence of the secondary probes. Moreover, previous findings 
using RNA-seq and nuclear enrichment of lncRNA showed that the lncRNA transcripts 
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are principally enriched in the cell nucleus in HepG2 cells (Derrien et al., 2012). 
Based on these previous results and on recent findings published by Cabili et al. (2015) on 
the variety of cellular lncRNA localisation patterns, the RNA FISH results provided here 
confirm the exclusively nuclear localisation of lnc-KDM5D-4:1 in HepG2 cells. The 
subcellular specification of lnc-KDM5D-4:1 suggests that this lincRNA plays a potential 
role in functions which take place within the nucleus (Maamar et al., 2013; Nickerson et 
al., 1989; Quinodoz & Guttman, 2014) such as the establishment and maintenance of 
nuclear domains like paraspeckles (Clemson et al., 2009), shaping of the 3D organisation 
(Engreitz et al., 2013; Quinodoz & Guttman, 2014), or acting as enhancer-like RNA by 
activating its neighbouring genes using a cis-mediated mechanism (Lai et al., 2013; Li et 
al., 2013) as described in Figure III.12. However, according to the results (Section 3.4.3) 
which show that the palmitate-induced upregulation of lnc-KDM5D-4 does not affect the 
expression of lnc-KDM5D-4 surrounding protein-coding genes, its possible role in the 
activation of those is then improbable, suggesting that this lincRNA possibly acts in trans 
rather than in cis. 
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Figure III.12: Mechanisms proposed for lincRNA function. Modes of action include 
cotranscriptional regulation (e.g., through either the interaction of factors with the nascent 
lincRNA transcript or the act of transcribing through a regulatory region), regulation of 
gene expression in cis or in trans through recruitment of proteins or molecular complexes 
to specific loci, scaffolding of nuclear or cytoplasmic complexes, titration of RNA-binding 
factors, and pairing with other RNAs to trigger posttranscriptional regulation. The two 
latter mechanisms are illustrated in the cytoplasm (where they are more frequently 
reported) but could also occur in the nucleus. Additional mechanisms will presumably be 
proposed as additional functions of lincRNAs are discovered (Taken from Ulitsky & 
Bartel, 2013). 
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To better understand the biological role of lnc-KDM5D-4 in the context of steatosis-
associated atherosclerosis, a knock-down experiment using GapmeRs was performed in 
HepG2 cells. The results demonstrated that the lnc-KDM5D-4 ‘probe I’ was the most 
efficient probe to knock-down lnc-KDM5D-4 located within the nucleus. This significant 
result also confirms the efficiency of the GapmeRs getting into the nucleus and targeting a 
nuclear lncRNA (Lennox and Behlke, 2016). 
The atherosclerosis RT2 Profiler PCR Array profiling the expression of 84 coding-genes 
related to atherosclerosis showed that silencing lnc-KDM5D-4 in HepG2 cells resulted in 
dysregulation of eleven genes; nine of these genes were found to be significantly 
upregulated (BIRC3, EGR1, MMP3, IL1A, BCL2, SERPINE1, VEGFA, PLIN2, ITGA2), 
and two genes were found to be significantly downregulated (ITGA5 and TNF) (Fig.III.9). 
Among the genes that were affected by lnc-KDM5D-4 knock-down in HepG2 cells, PLIN2 
is implicated in lipid metabolism. This protein coding gene is located on chromosome 9 
and belongs to the perilipin family, members of gene which regulate intracellular lipid 
storage droplets and very low-density lipoprotein (VLDL) secretion (Magnusson et al., 
2006). Overexpression of PLIN2 has been shown to trigger an increase in lipid droplets 
formation in hepatocytes via the up-regulation of the peroxisome proliferator-activated 
receptor gamma isoform (PPAR) (Rogue et al., 2011). Furthermore, the upregulation of 
PLIN2 was previously associated with liver steatosis (Okumura, 2011) and atherogenesis 
(Chawla et al., 2001). More recently, PLIN2 expression was also associated with 
atherosclerosis in patients with carotid stenosis (Perisic et al., 2016). On the other hand, 
the loss of PLIN2 has resulted in reduction of liver steatosis and inflammation (Najit et al., 
2016). Also, according to these results, the ‘anti-apoptosis’ pathway was the most 
dysregulated pathway represented, as summarised in Figure III.10, involving the 
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following anti-apoptotic genes BIRC3, IL1A, BCL2 and TNF. The results demonstrate 
notably that silencing lnc-KDM5D-4 triggers a significant (p=0.000025) strong increase 
(Fold regulation=12.45) in the expression of BIRC3 (Baculoviral IAP repeat containing 3) 
compared to all the dysregulated genes. Concomitantly BIRC3 protein-coding gene is 
located on chromosome 11 and its transcripts were found to be more expressed in the 
nucleus than in the cytoplasm (GeneCards, Human Gene Database). This information is 
correlated with previous findings and hypothesis noted in this chapter which identified lnc-
KDM5D-4:1 as a nuclear-retained lincRNA with potential role of gene regulation in trans. 
BIRC3, also known as IAP-1 (Inhibitor of apoptosis protein 1), is known to inhibit 
apoptosis (Liston et al., 1996; Rothe et al., 1995). In the context of atherosclerosis, BIRC3 
was found to be expressed by vascular smooth muscle cells and macrophage foam cells of 
the inflamed vascular wall but not expressed in normal arteries which do not display 
monocytes/macrophage infiltrates (Horrevoets et al., 1999). Precisely, BIRC3 protein 
blocks TNF-α receptor-mediated cellular apoptosis. TNF-α also known as TNF (Tumor 
necrosis factor) is known for its ability to induce apoptosis in a lot of cell types under certain 
conditions through activation of its cognate receptor subtype I (Clem et al., 1997; 
Horrevoets et al., 1999). Experiments on human aortic atherosclerotic lesions hypothesised 
that the vascular cell protects itself efficiently against TNF-α–induced apoptosis by 
expressing BIRC3 that is able to block cellular apoptosis (Chu et al., 1997; Deveraux et al., 
1998). In the cellular pathway, BIRC3 inhibits apoptosis through the MAPK and NF-κB 
signaling pathways (Gan et al., 2016; Mehrotra et al., 2010) promoting inflammation in the 
vascular cells of the artery wall (Horrevoets et al., 1999) which can trigger atherosclerosis. 
Together, these previous findings support the results of the PCR array. The silencing of 
lnc-KDM5D-4 in HepG2 cells inhibits apoptosis through the upregulation of BIRC3, IL1A 
and BCL2, and the downregulation of TNF. Furthermore, the upregulation of MMP3 
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(Matrix metallopeptidase 3) (Fig.III.9) is correlated by the fact that, although it is known 
to be involved in cancer progression and tissue remodeling (Sternlicht & Werb, 2001), this 
protease is also involved in apoptosis in many type of cells and diseases (Kmiecik et al., 
2015; Zhao et al., 2015), and notably in human liver cells (Si-Tayeb et al., 2006). MMP3 
is also involved in the pathogenesis of CAD as a marker of inflammation in the premature 
coronary atherosclerosis (Nanni et al., 2007). The list of transcription factors provided by 
the PCR array (Appendix 3.9) proposes lnc-KDM5D-4 as the potential candidate factor of 
transcription responsible for the changes of gene expression in future research. 
Regarding the potential tissue-specific functional interaction network of BIRC3 generated 
by GIANT (Fig.III.11), results suggest that BIRC3 interact with the following genes: LIF, 
BPGM, ENSA, STX7, CRYM, GLO1, and ETHE1 in human hepatocytes. Among them, LIF 
(Leukemia inhibitor factor) is the only gene associated with atherosclerosis and CAD 
according to the literature to date. This protein-coding gene was found to be involved in the 
prevention of the progression of the pre-formed atherosclerotic plaques in humans (Rolfe et 
al., 2003). Therefore, the protein-coding genes BPGM, ENSA, STX7, CRYM, GLO1, and 
ETHE1 should be taken into consideration for future works on BIRC3, lnc-KDM5D-4 and 
atherosclerosis. 
Overall, these findings provide the first evidence for the involvement of a Y-chromosome-
linked lincRNA as a regulator of lipid metabolism and IAP-related genes. Nevertheless, 
additional work on lnc-KDM5D-4 overexpression in HepG2 cells should be performed to 
confirm the regulation of PLIN2 and BIRC3 by this lincRNA. Interestingly, BIRC3 is also 
studied as an IAP gene in cancer (Gan et al., 2016). IAP genes are known to be critical 
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regulators of several pathways that control cell death, proliferation, and differentiation. 
These genes can also regulate innate and adaptive immunity through modulation of signal 
transduction pathways, cytokine production, and cell survival. IAP genes regulate 
apoptosis through controlling caspase activity (Berthelet & Dubrez, 2013) and promote 
metastasis through NF-κB-induced alterations in cell mobility signalling (Mehrotra et al., 
2010). In this context, a lot of research has been performed on the inhibition of IAP genes 
in combatting cancer to inhibit cell proliferation and activate apoptosis, with antagonists 
for the treatment of immune disorders currently being studied (Beug et al., 2012). 
Moreover, among the genes interacting with BIRC3 (Fig.III.11), two genes, ENSA 
(endosulfine alpha) and GLO1 (glyoxalase I), are particularly known to be implicated in 
cancer. ENSA was found to play a role in liver cancer propagation (Chen et al., 2013). As 
for GLO1, it was recently found to be involved in tumour cell proliferation and survival, 
suggesting its role as a potential biomarker for tumour diagnosis and a target for anticancer 
therapy especially in HCC (Geng et al., 2014; Zhang et al., 2014). 
Taking the aforementioned data into consideration, the Y-linked lnc-KDM5D-4 should be 
an interesting potential novel target for cancer treatment or immune disorders, specifically 
as a potential inhibitor of the IAP gene BIRC3. Additional works should be performed to 
elucidate the molecular mechanism of attenuation of BIRC3 by lnc-KDM5D-4. 
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4. TRANSCRIPTOME ANALYSIS IN A CELL MODEL OF
ATHEROSCLEROTIC CORONARY ARTERY SMOOTH
MUSCLE CELLS
4.1 ABSTRACT 
Background: Atherosclerosis is the leading underlying cause of coronary artery disease 
(CAD) which is the major cause of morbidity and mortality worldwide. However, the 
pathogenesis of vascular complications of CAD is not well understood. Although CAD has 
well-defined environmental risk factors, genome-wide association studies (GWAS) have 
demonstrated a genetic influence on CAD. Recent studies have shown that the human Y 
chromosome is associated with a greater risk of CAD in men but no Y-linked gene has 
been investigated in this disease so far. Aims: The aim of this study is to examine the 
transcriptome of human atherosclerotic coronary artery smooth muscle cells and to 
investigate the expression of Y chromosome genes in these cells in comparison to healthy 
cells. Methods: Using an in vitro human primary cell model of atherosclerotic coronary 
artery smooth muscle cells (D-CASMC) and non-atherosclerotic cells (CASMC), a 
transcriptome analysis between the two cell types was performed using RNA sequencing 
(RNA-seq). The difference of expression of the Y-linked genes between those was studied 
by quantitative PCR (qPCR). Results: RNA-seq analysis revealed that the whole Y 
chromosome is significantly underexpressed in D-CASMC compared to CASMC; this was 
confirmed by the qPCR results. Furthermore, in D-CASMC, RNA-seq, qPCR and RNA 
FISH experiments confirmed the decrease in the expression of the Y-linked pseudogene 
PRKY which was recently found to be downregulated in the macrophages in CAD in men. 
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Conclusion: This study is the first to investigate human Y chromosome transcripts in a 
cell model of atherosclerotic coronary artery smooth muscle cells, and to show an 
underexpression of PRKY in CAD. Overall, this study provides the first evidence for the 
loss or repression of a human chromosome in relation to CAD. 
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4.2 INTRODUCTION 
Atherosclerosis is a vascular disease in which the artery wall thickens as a result of invasion 
and accumulation of foam cells and proliferation of intimal smooth muscle cells creating a 
fatty plaque. Within coronary arteries, over time, this buildup of plaques progressively 
hardens and narrows the blood vessels leading to coronary artery disease (CAD) (Sakakura 
et al., 2013). As a consequence, thrombosis of the vessels or stenosis can occur leading to 
angina pectoris and /or myocardial infarction (Roger et al., 2012). Although CAD is the major 
cause of morbidity and mortality in the world according to the latest report of the Global 
Burden of Disease ([GBD], 2015) the molecular mechanisms that promote CAD in 
individuals are not well understood. CAD is a multifactorial and complex late-onset disease 
which originates from a complicated interplay of environmental and genetic factors. This 
disease is a highly heritable trait, with genetic and environmental factors accounting for 
similar proportions of individual susceptibility (Kathiresan et al., 2012; Stylianou et al., 
2012). Over the last ten years, genome-wide association studies (GWAS) have been able to 
demonstrate a genetic influence on CAD in addition to association studies suggesting that 
the human Y chromosome harbour genes that contribute to CAD in men (Charchar et al., 
2012). Due to the haploid nature of the Y chromosome, the usual methods of analysis such 
as GWAS cannot be employed to investigate variations, resulting in the Y chromosome 
being routinely excluded from large-scale GWAS; making the Y chromosome the most 
underexplored portion of the human genome to date. Thus, to better apprehend the 
implication of the Y chromosome in CAD in men, after having studied the involvement of 
the Y-linked lincRNA in steatosis-associated atherosclerosis using HepG2 cells as cell 
model for atherosclerosis (Chapter 3), I moved on another human cell model in CAD 
research, the human primary coronary artery smooth muscle cells, atherosclerotic (diseased, 
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as D-CASMC) and non-atherosclerotic (normal, as CASMC). Both of these cells have been 
used for experimental applications in vascular research, stroke, diabetes, atherosclerosis, and 
hypertension (Van der Meer et al., 2011). Because of their involvement in the process of 
atherosclerosis (both come from Caucasian males), these cells are suitable and relevant 
models to study the Y-linked genes, intracellular trafficking and dynamics of CAD in men 
in vitro. The aims of this study are (1) to study the difference of expression in regards to the 
transcriptome between the atherosclerotic and non-atherosclerotic cells, and (2) to 
investigate the difference of expression of the Y chromosome genes in these cells by RNA 
sequencing and qPCR gene expression analysis. Finally, some of the results were validated 
by RNA FISH. These experiments are described in Chapter 4. 
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4.3 METHODOLOGY 
Section 4.3 and all associated material has been removed 
at the author's request
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4.4 RESULTS 
 
4.4.1 Human primary smooth muscle cell RNA sequencing 
 
4.4.1.1 Expressed transcripts 
 
RNA sequencing results demonstrated that 39,642 transcripts from 14,871 genes were 
expressed in both sample groups, CASMC and D-CASMC, across all chromosomes. [Note: 
the variety and functional qualities of these genes have not been characterised further, 
except for those found to be differentially expressed].   
 
4.4.1.2 Expression of Y chromosome transcripts 
 
16 genes and 47 transcripts were expressed on the Y chromosome in all samples. Figure 
IV.1 highlights the marked underexpression of all Y chromosome transcripts in the D-
CASMC sample group compared to CASMC. There were few orange tiles for the D-
CASMC samples. This chromosome-specific pattern was unique to the Y chromosome 
(Fig.IV.2).  
 
 
147 
148 
 
Figure IV.1: Heatmap of Y chromosome transcript expression in D-CASMC and 
CASMC samples. Orange indicates expression above the mean and blue expression below 
the mean. ‘z_count’ is reflected in tile colour and is derived from the Z-transformed log2 
read count for each transcript. It reflects the number of standard deviations departure from 
the mean for each transcript.  
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Figure IV.2: Number of transcripts with positive (1) or negative (-1) differences in 
mean expression in the D-CASMC group compared to CASMC. These values are 
irrespective of statistical significance of the difference in mean expression. Data is plotted 
per chromosome using the sign (positive (orange bar labelled “1”) or negative (blue bar 
labelled “-1”) of the t-statistic from a linear model fit for all transcripts. 
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4.4.1.3 Differentially expressed transcripts 
 
Results showed that 2,634 transcripts produced by 2,191 genes were differentially 
expressed between the sample groups. Seven of these transcripts were derived from the Y 
chromosome. Figure IV.3 shows the number of differentially expressed transcripts per 
chromosome and highlights the number that were under and over expressed in the D-
CASMC samples. 
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Figure IV.3: Number of differentially expressed transcripts over (1) or under (-1) 
expressed in the D-CASMC group compared to CASMC. Data is plotted per 
chromosome using the sign (positive (orange bar labelled “1”), or negative (blue bar 
labelled “-1”) of the t-statistic from a linear model fit for all transcripts. 
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4.4.1.4 Differentially expressed Y chromosome transcripts 
 
The following seven Y chromosome transcripts, RPS4Y1-002, USP9Y-002, DDX3Y-003, 
TXLNGY-012, RPSAY1-001, NLGN4Y-001 and PRKY-001 were found to be 
differentially expressed between the two sample groups (see Fig.IV.4 and Table IV.3). 
All of these transcripts were significantly underexpressed in the D-CASMC group 
compared to CASMC group.  
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Figure IV.4: Heatmap of differentially expressed Y chromosome transcripts in D-
CASMC and CASMC samples. Orange indicates expression above the mean and blue 
expression below the mean. ‘z_count’ is reflected in tile colour and is derived from the Z-
transformed log2 read count for each transcript. It reflects the number of standard 
deviations departure from the mean for each transcript.  
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Table IV.3: Differential expression summary information for Y chromosome 
transcripts. Seven Y chromosome transcripts in total were found to be differentially 
expressed between the two sample groups. The following five transcripts are from protein 
coding genes: RPS4Y1-002, USP9Y-002, DDX3Y-003, RPSAY1-001 and NLGN4Y-001. 
The following two transcripts are from non-protein coding genes: TXLNGY-012 and 
PRKY-001. All are significant at FDR <0.05 in all bootstrap replicates. Transcripts are 
ordered by degree of statistical significance. 
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4.4.1.5 Gene sets differentially expressed between CASMC and D-
CASMC 
 
Differential expression statistics between the two sample groups, CASMC and D-CASMC, 
were used to generate input for a pre-ranked GSEA. This was performed at the gene-level 
to look for coordinated trends of expression in groups of genes known to have similar 
properties. The data was compared to the “Hallmark” and combined “BioCarta”, 
“Reactome” and “KEGG” (referred to collectively as “Pathway”) gene set collections. The 
“Hallmark” gene set collection contains a set of well characterised high-level biological 
states and processes and therefore serves as a starting point for the gene set enrichment 
testing. The “Pathway” gene set collection provides greater detail but can also include 
conflicting and correlated gene sets. There was significant evidence of coordinated changes 
in expression between the sample groups with 14 upregulated and 12 downregulated 
“Hallmark” gene sets in the D-CASMC sample group (Table IV.4). Additionally, 124 
“Pathway” gene sets were upregulated with 11 downregulated. All gene sets up or down 
regulated at FDR <0.05 were considered significant.  
Results from the “Hallmark” collection indicate upregulation of core cellular functions 
(glycolysis, cell cycle, DNA organisation) as well as tissue specific reorganisation 
(epithelial mesenchymal transition, myogenesis, apical junction), specific regulatory 
complexes (MYC, mTORC1) and environmental responses (hypoxia, unfolded protein 
response). 
Downregulated gene sets include responses to common cytokines (IFN-α, IFN-γ, TNF-α), 
environmental responses (reactive oxygen species, inflammatory response) and general 
indicators of a modified immune response (Complement, IL2/STAT5 signalling, 
IL6/STAT3 signalling). 
Significant results from the “Pathways” collection agree strongly with the “Hallmark” 
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results. The general theme of upregulated core cellular functions (e.g. glucose metabolism, 
ribosome, DNA replication) and tissue reorganisation replicate well (e.g. collagen 
formation, focal adhesion, gap junction). The downregulated gene sets also agree well with 
the “Hallmark” results, indicating a downregulation of response to cytokines (e.g. 
cytokine/cytokine receptor interaction, signalling by interleukins) and the immune 
response in general (e.g. arachidonic acid metabolism, complement and coagulation 
cascades). 
All significant gene sets from the “Pathways” collection were analysed for overlapping 
gene membership, the resultant gene set relationships (Fig.IV.5) was visualised as a 
weighted undirected network. Gene sets are represented as nodes and gene membership 
overlap between gene sets is represented as weighted edges connecting the nodes. 
The “Pathways” collection network (Fig.IV.5) identifies a high degree of interconnectivity 
between the upregulated gene sets, suggesting a global and coordinated change in overall 
cell state. This is not reflected in the downregulated gene sets, which suggests isolated 
changes in specific components of cellular activity. 
The “Hallmark” collection was found to only have minor gene membership overlap 
between gene sets, highlighting the high-level and unique nature of each of its gene sets 
(data from this collection is not shown). 
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Table IV.4: All significant (FDR < 0.05) gene sets from the “hallmark” collection.  
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Figure IV.5: Gene set membership overlap network for “Pathways” collection. All 
significantly up or down regulated gene sets are shown as nodes with edges between gene 
sets with an overlap coefficient of 0.4. 
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4.4.2 Gene expression comparison between CASMC and D-CASMC 
 
4.4.2.1 Differentially expressed Y-linked lincRNAs and PRKY 
 
Based on RNA sequencing results, PRKY was preferentially chosen as a new functional 
candidate for the development of CAD in men since this pseudogene is, firstly, a lncRNA 
gene, and, secondly, it has been found to be under-expressed in the macrophages of men 
with CAD (Bloomer et al., 2013).  
 
The expression of PRKY and selected Y-linked lincRNAs (previously studied in Chapters 
2 & 3) were studied by qPCR in CASMC and D-CASMC sample groups [Note: the same 
replicate samples as for the RNA sequencing assay were used for this experiment]. 
Firstly, qPCR analysis showed that PRKY and all the Y-linked lincRNAs studied here were 
expressed in coronary artery smooth muscle cells (CASMC), except for the transcript ZFY-
1:3 which is not expressed in any cell groups (data not shown). Furthermore, results 
showed a significant decrease in the expression of PRKY and lincRNAs studied in D-
CASMC samples in comparison to the control cells CASMC (Fig.IV.6). CT results were 
normalised with the two HKGs, GAPDH and ACTB, with similar patterns of expression 
change obtained with both sets of genes. [Note: only results from GAPDH are represented 
here]. 
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Figure IV.6: qPCR analysis of the Y-linked lncRNA transcript expression between  
D-CASMC and CASMC. The level of transcript expression of lnc-KDM5D-4:1, lnc-
ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, lnc-RBMY1J-1:3, lnc-
RBMY1B-1:1, lnc-RBMY1B-1:4 and PRKY is significantly decreased in D-CASMC in 
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comparison of CASMC (Fold Changes and p-values in Appendix 4.4). Expression relative 
to GAPDH. Error bars indicate ±SD; n=3. Student’s t-test: ** p<0.01, *** p<0.001. 
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4.4.2.2 Differentially expressed Y-linked protein-coding genes 
 
To investigate whether the Y-linked protein-coding genes have a similar pattern of 
expression changes as previously shown with the Y-linked lincRNAs within D-CASMC, 
the transcript level of the Y-linked protein-coding genes previously studied in Chapter 3 
(Table III.1) were studied by qPCR in CASMC and in D-CASMC. The expression of UTY 
and KDM5D genes previously suspected to be implicated in CAD through immunity 
inflammatory response by macrophages in men (Bloomer et al., 2013; Kruidenier et al., 
2012) were also studied.  
 
Firstly, qPCR analysis showed that BPY2, DAZ1, DAZ2, KDM5D, PRY, PRY2, and UTY 
were expressed in coronary artery smooth muscle cells (CASMC). No expression was 
found for RBMY1J and RBMY1F in both cell groups (data not shown). Furthermore, 
results showed that all the genes were significantly decreased in the expression in D-
CASMC in comparison to the control cell group CASMC (Fig.IV.7). CT results were 
normalised with the two HKGs, GAPDH and ACTB, with similar patterns of expression 
change obtained with both sets of genes. [Note: only results from GAPDH are represented 
here]. 
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Figure IV.7: qPCR analysis of the Y-linked coding transcript expression between  
D-CASMC and CASMC. The level of transcript expression of BPY2, DAZ1, DAZ2, 
PRY, PRY2, UTY and KDM5D is significantly decreased in D-CASMC in comparison of 
CASMC (Fold Changes and p-values in Appendix 4.4). Expression relative to GAPDH. 
Error bars indicate ±SD; n=3. Student’s t-test: *** p<0.001. 
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4.4.2.3 Differentially expressed atherosclerosis-related genes 
 
The lncRNA ANRIL (located on chromosome 9) and the protein-coding gene PCSK9 
(located on chromosome 1) have been previously found to be implicated in CAD (Holdt et 
al., 2010; Li et al., 2015). Therefore, the expression of these genes was studied by qPCR 
in CASMC and in D-CASMC. The qPCR analysis showed that ANRIL and PCSK9 were 
significantly decreased in the expression in D-CASMC in comparison to the control cells, 
CASMC (Fig.IV.8). CT results were normalised with the two HKGs, GAPDH and ACTB, 
with similar patterns of expression change obtained with both sets of genes. [Note: only 
results from GAPDH are represented here]. 
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Figure IV.8: qPCR analysis of ANRIL and PCSK9 transcript expression between  
D-CASMC and CASMC. The level of transcript expression of ANRIL and PCSK9 were 
significantly decreased in D-CASMC in comparison of CASMC (Fold Changes and p-
values in Appendix 4.4). Expression relative to GAPDH. Error bars indicate ±SD; n=3. 
Student’s t-test: *** p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
166 
 
4.4.3 Subcellular expression comparison and localisation of PRKY 
transcripts 
 
The two following experiments have been done at the same time, in parallel. 
 
4.4.3.1 PRKY differentially expressed between CASMC and D-CASMC 
 
Since little is known about the function of the PRKY, a RNA FISH assay (QuantiGene® 
ViewRNA assay, Affymetrix®) targeting PRKY transcripts was performed in CASMC and 
D-CASMC to (1) validate the RNA sequencing analysis and qPCR results, and to (2) 
determine PRKY transcripts cellular localisation in vascular smooth muscle cells (Section 
4.4.3.2). The expression of PRKY was compared between both cell groups. The assay was 
performed with addition of glacial AA to the fixation solution. The nucleus was stained in 
blue with DAPI.  
 
Firstly, results showed that PRKY (red fluorescence) is expressed in human coronary artery 
smooth muscle cells (Fig.IV.9 E&F), with a strong decrease of signals for PRKY observed 
in D-CASMC (Fig.IV.9 F) in comparison to CASMC (Fig.IV.9 E), although no similar 
results were observed for the positive control, ACTB (green fluorescence) (Fig.IV.9 
C&D). Furthermore, a decrease in the number of cells was noticed in all wells with D-
CASMC (Fig.IV.9 B, D&F) compared to wells containing CASMC (Fig.IV.9 A, C&E), 
although the same number of cells were seeded at the beginning of the RNA FISH assay. 
This could be due to an increased sensitivity in the physiology of D-CASMC compared to 
CASMC. 
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4.4.3.2    Subcellular localisation determination of PRKY in human 
coronary artery smooth muscle cells 
 
So far, although PRKY was first annotated in 1997 by Schiebel et al., its subcellular 
localisation in human cells is still undiscovered. Therefore, an RNA FISH, QuantiGene® 
ViewRNA assay (Affymetrix®), was performed to study PRKY RNA localisation into the 
coronary artery smooth muscle cells by using CASMC.  
Results showed that the fluorescence (red) of a single-RNA molecule of PRKY displays 
both a nuclear and cytoplasmic distribution in CASMC (Fig.IV.9 E; Fig.IV.10 E) with a 
nuclear predominance as shown in zoomed images (Fig.IV.10 I&J). Furthermore, results 
obtained without the addition of AA (Fig.IV.10 G&H) allowed us to see and confirm the 
PRKY cytoplasmic expression, as expected according to the observations made with 
previous results in HepG2 cells and the amendment of the permeabilisation procedure 
(Section 3.4.5) 
RNA FISH results were then confirmed by qPCR using nuclear and cytoplasmic RNAs 
separately isolated from CASMC, as shown in Fig. IV.11. 
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Figure IV.9: PRKY expression comparison by RNA fluorescence in situ hybridisation 
within CASMC and D-CASMC. 
A, C, E) results in CASMC. B, D, F) results in D-CASMC. A, B) Cells without probes 
A B
C D 
E F 
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(negative control). C, D) ACTB FISH (green) used as housekeeping gene and positive 
control for the RNA FISH assay. E, F) RNA FISH shows the subcellular localisation of 
PRKY RNA (red) and its differential expression between CASMC (E) and D-CASMC (F). 
Assay realised with glacial AA (1%) added to the fixation. Images represent 2 independent 
experiments. Confocal microscope magnification: 20x.   
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Figure IV.10: PRKY subcellular localisation by RNA fluorescence in situ 
hybridisation within CASMC.  
G, H) RNA FISH shows the cytoplasmic localisation of PRKY RNA (red) in cells without 
acetic acid. E, I, J) RNA FISH shows the cytoplasmic and nuclear localisation of PRKY 
RNA (red) in cells with acetic acid (1%). Nucleus stained in blue (DAPI). Confocal 
microscope magnification: 20x. Negative control (cells without probe) and positive control 
(ACTB FISH (green)) are represented in Figure IV.9. [Note: the image E is the same image 
as image E in Figure IV.9]. 
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Figure IV.11: Cytoplasmic and nuclear PRKY relative expression in CASMC. qPCR 
PRKY transcript expression results from nuclear and cytoplasmic RNAs isolated 
separately from CASMC before reverse transcription, then qPCR. Results show a shared 
expression between nucleus and cytoplasm of PRKY with slightly more in the nucleus. 
Expression of ACTB (control) is approximately half nuclear and half cytoplasmic. 
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4.5 DISCUSSION 
 
The main aim of this chapter was to analyse the transcriptome of human coronary artery 
smooth muscle cells, atherosclerotic and non-atherosclerotic, and especially to study the 
differential expression of the pseudogene PRKY as well as its subcellular localisation in 
these cells in vitro. The main findings of this part of my thesis suggest that the human Y 
chromosome is underexpressed in the atherosclerotic coronary artery smooth muscle cells 
(D-CASMC), and the Y-linked pseudogene PRKY, whose transcripts are expressed in both 
the cytoplasm and nucleus of vascular smooth muscle cells, is downregulated in these cells 
compared to the non-atherosclerotic cells. The research performed in this chapter was the 
first study (1) to work on a human Y chromosome transcript analysis on atherosclerotic 
and healthy coronary artery smooth muscle cells, (2) to show an underexpression of the 
pseudogene PRKY in CAD and to determine its subcellular localisation in these smooth 
muscle cells, (3) to provide evidence for the loss or repression of a human chromosome in 
relation to CAD. 
  
D-CASMC exhibit the low shear stress region profile of coronary plaque. 
Using RNA sequencing analysis, gene set enrichment was used to look for coordinated 
trends in differential expression of genes between the two samples, CASMC and D-
CASMC (Fig.IV.5). Results showed that downregulated gene sets include responses to 
common cytokines (IFN-α, IFN-γ, TNF-α), environmental responses (reactive oxygen 
species, inflammatory response), and general indicators of a modified immune response 
(Complement, IL2/STAT5 signaling, IL6/STAT3 signalling). In summary, signals of 
overall cellular activity (metabolism of protein, RNA and carbohydrate, cell cycle, DNA 
replication) were significantly upregulated in the D-CASMC sample group as well as 
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pathways related to the extracellular matrix, tissue organisation and myogenesis. On the 
other hand, pathways related to the blood coagulation, reactive oxygen species (ROS), and 
response to external cytokines were significantly downregulated. According to these 
results and based on previous research on vascular smooth muscle cells in atherosclerosis 
(Chistiakov et al., 2015), the atherosclerotic cells, D-CASMC, used in this study come 
from the downstream lesion regions, also called low (oscillatory) shear stress region, of 
the atherosclerotic plaque in the coronary artery. This is caused by the plaque activating 
vascular smooth muscle cell proliferation through the Transforming Growth factor beta 
(TGF-β), Insulin-like growth factor-1 (IGF-1) and Platelet-derived growth factor (PDGF) 
released by the endothelial cells in this region. Vascular smooth muscle cells are not 
terminally differentiated, and hence exhibit phenotypic and functional plasticity to respond 
to vascular injury. This feature discriminates these cells from skeletal muscle cells and 
cardiomyocytes that are terminally differentiated. Therefore, in chronic inflammation that 
occurs in atherosclerosis, arterial vascular smooth muscle cells become aberrantly 
regulated leading to increased vascular smooth muscle cells dedifferentiation and 
extracellular matrix formation in plaque areas. This is supported by the results of this 
Chapter 4.  
 
Underexpression of the entire Y chromosome in primary atherosclerotic coronary 
artery smooth muscle cells. 
Previously studied through sequencing by Cabili et al. (2011), the following Y-specific 
lincRNA transcripts: lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-
RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-1:3 have been 
identified for the first time by qPCR gene expression analysis in human coronary artery 
vascular smooth muscle cells (Fig.IV.6). The Y-linked protein coding genes BPY2, DAZ1, 
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DAZ2, PRY, PRY2, UTY, and KDM5D have been identified for the first time by qPCR gene 
expression analysis in these cells (Fig.IV.7). The expression comparison of these genes 
between healthy and atherosclerotic cells (CASMC and D-CASMC respectively) revealed 
that they were all significantly downregulated in D-CASMC compared to CASMC. The 
downregulation of PRKY and UTY support the previous findings on macrophages and CAD 
by Bloomer et al. (2013), and the qPCR results were correlated with those from the RNA 
sequencing analysis (Section 4.4.2). Furthermore, RNA-seq determined a significant 
downregulation of seven transcripts from six Y chromosome genes, including the protein-
coding genes USP9Y, RPS4Y1, NLGN4Y, and DDX3; and the non-protein-coding genes 
(pseudogenes), TXLNGY and PRKY. By comparing their position along the Y chromosome, 
we can observe that TXLNGY (Yq11.222) and PRKY (Yp11.2) are surrounding the protein-
coding genes NLGN4Y (Yq11.221) and DDX3 (Yq11.0) respectively. Further work needs 
to be done to know if these pseudogenes could be regulating their neighbouring protein-
coding genes. Even with differential expression between sample groups, we would always 
expect to see roughly similar numbers of over and under expressed transcripts per 
chromosome. However, the results of the assessment of transcript expression per 
chromosome (Fig.IV.2) shows roughly similar numbers of under and overexpressed 
transcripts per chromosome, except on the Y chromosome. This indicates two possibilities; 
either there are regulatory functions acting to reduce expression of all loci on the Y 
chromosome in unison, or there has been a partial loss of the Y chromosome from the D-
CASMC cell population. This question could be addressed with a multi-locus qPCR to 
look for variations in copy number. The phenomena of loss of the Y chromosome has 
actually never been observed in atherosclerosis or CAD to date but has been described in 
various male-biased diseases (Appendix 4.5), notably in aging (Aviv et al., 2001), 
haematology disorders (Huh et al., 2007) and in cancer (Kido & Lau, 2015). However, 
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only two cell groups are not really sufficient to be able to conclude on the downregulation 
of the Y chromosome in atherosclerotic coronary artery smooth muscle cells. Further work 
with more samples need to performed to confirm the potential loss of the Y chromosome 
in CAD in men. 
 
ANRIL and PCSK9 are downregulated in primary atherosclerotic coronary 
smooth muscle cells. 
ANRIL, so far the most replicated marker of CAD independent from the conventional risk 
factors (Holdt et al., 2010), and PCSK9, a well-known protein-coding gene implicated in 
cholesterol disorders and atherosclerosis (Li et al., 2015), were studied (Fig.IV.8) as 
positive control genes for the experiments on CAD in this Chapter. The expression 
comparison by qPCR of these genes between CASMC and D-CASMC revealed that they 
were both significantly downregulated in D-CASMC compared to CASMC. Results 
regarding ANRIL confirm previous research on CAD and ANRIL in vascular smooth 
muscle cells by Motterle et al. (2012). However, this study provides the first evidence of 
the downregulation of PCSK9 in primary atherosclerotic coronary smooth muscle cells as 
there are no correlated results published to date on this gene. Therefore, further studies 
should be performed to understand why PCSK9 is downregulated in these cells, whereas it 
has been found to be upregulated in the liver in hypercholesterolemia (Lambert et al., 
2009), and to promote inflammation and endothelial dysfunction in atherosclerosis (Denis 
et al., 2012). 
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PRKY displays nuclear and cytoplasmic distribution, and is underexpressed in 
primary vascular smooth muscle cells in CAD. 
The decrease in the expression of the pseudogene PRKY has been demonstrated by RNA 
seq (Fig.IV.4) and confirmed for the first time using qPCR gene expression analysis 
(Fig.IV.6) and also by RNA FISH (Fig.IV.9) in atherosclerotic and non-atherosclerotic 
vascular smooth muscle cells. These results support the recent findings made by Bloomer 
et al. (2013) on the downregulation of PRKY in macrophages in CAD. To foster a 
hypothesis for potential molecular roles of PRKY in CAD, its subcellular localisation was 
studied by RNA FISH in CASMC (Fig.IV. 9&10). Results using ACTB (Fig.IV.9 C&D) 
confirm the efficiency of reagents and method used in this assay. Moreover, the results with 
or without AA (Fig.IV.10 G&H and Fig.IV.10 E,I&J, respectively) confirm the previous 
results from Chapter 3 on the fact that AA does not influence the cytoplasmic RNA signal 
but allows a nuclear RNA signal. For negative controls, wells with only secondary probes 
were tested and no signal displays were shown as expected (Fig.IV.9 A&B), confirming 
that the signals obtained for ACTB and PRKY were relevant and not identified as the cause 
of a potential fluorescence of the secondary probes. Furthermore, RNA FISH results were 
then confirmed by qPCR using nuclear and cytoplasmic RNAs, separately isolated from 
CASMC, as shown in (Fig.IV.11). Therefore, these results provide the first evidence of 
PRKY subcellular localisation being more nuclear than cytoplasmic in vascular smooth 
muscle cells.  
 
Overall, these findings support evidence for the implication of the human Y chromosome 
in atherosclerosis and CAD. These results highlight the importance to further study the Y 
chromosome which is too often excluded from research into the genetics of CAD (Molina 
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et al., 2016). Further studies should focus on the role of the Y chromosome, especially PRKY 
in vascular smooth muscle cells to better understand its potential implication as pseudogene 
in the mechanisms of the pathogenesis and the genetics of CAD in men. This would help us 
to better understand the complex interplay between the human Y chromosome, immunity, 
and cardio vascular disease; and maybe discover new diagnostic markers and therapeutic 
targets for CAD in men in the future. 
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5. CONCLUSIONS & FUTURE STUDIES 
 
 
5.1 DISCUSSION SUMMARY  
 
The main aim of this thesis was to investigate the relationship between the human Y 
chromosome, lncRNAs and CAD to gain a better understanding of the causative molecular 
mechanisms of CAD pathophysiology in men.   
 
In my first study (Chapter 2), I identified for the first time through gene expression analysis 
(qPCR) the expression of the following Y chromosome-linked lincRNAs across 21 different 
normal, human tissues including WBCs: lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-
ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2 and 
lnc-RBMY1J-1:3. This study highlights a new knowledge about Y chromosome-linked 
lincRNA expression by providing a novel expression profile for these lincRNA transcripts 
in different human tissue types such as adipose, bladder, brain, cervix, colon, esophagus, 
heart, kidney, liver, lung, ovary, placenta, prostate, skeletal muscle, small intestine, spleen, 
testes, thymus, thyroid, and trachea. Furthermore, qPCR analysis showed that the Y 
chromosome-linked lincRNAs lnc-KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, 
lnc-RBMY1B-1:1, lnc-RBMY1B-1:4, and lnc-RBMY1J-1:3 were expressed in male 
leukocytes. Hence, these lincRNAs could be potential non-protein coding gene candidates 
for CAD research and in leukocytes such as macrophages. 
Having provided novel data on the expression profile of the Y-linked lincRNAs lnc-
KDM5D-4:1, lnc-ZFY-1:1, lnc-ZFY-1:3, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-
1:4, lnc-RBMY1J-1:1, lnc-RBMY1J-1:2, and lnc-RBMY1J-1:3 across 20 human tissues 
including and leukocytes; and highlighted potential novel Y-linked lincRNA candidates 
for CAD, and knowing that the Y chromosome contributes to lipid levels in humans, 
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therefore I then explored the potential function of selected Y-linked lincRNAs in a fatty 
liver context (steatosis-associated atherosclerosis). This was performed using the human 
hepatoma cell line, HepG2, the human model of liver cells in CAD (Chapter 3). This study 
showed for the first time the expression of the Y-linked lincRNAs lnc-KDM5D-4:1, lnc-
ZFY-1:1, lnc-ZFY-2:1, lnc-RBMY1B-1:1, lnc-RBMY1B-1:4 in HepG2 cells. Furthermore, 
this research corroborated the involvement of the Y-chromosome-linked lincRNA lnc-
KDM5D-4 in steatosis-associated atherosclerosis and its retained-nuclear cellular 
localisation in human hepatocytes, suggesting a role which takes place in the cell nucleus. 
Finally, this study provides the first evidence for the involvement of a Y-chromosome-
linked lincRNA as a potential regulator of PLIN2 and BIRC3 in hepatocytes; BIRC3 being 
known to be implicated in the inflammatory process of atherosclerosis and CAD in 
vascular smooth muscle cells. 
 
Having shown that a Y chromosome-linked lincRNA could be involved in the determination 
of lipid level and hence atherosclerosis in men, and to further explore the role of lnc-
KDM5D-4, I also sought to determine if this Y-linked lincRNA was also accounted for in 
human coronary artery smooth muscle cells, especially in atherosclerotic coronary artery 
cells, and also to determine if other non-coding RNAs were also involved, such as PRKY 
which was previously considered as a new functional candidate for the development of 
CAD (Chapter 4). By analysing the transcriptome of human atherosclerotic and non-
atherosclerotic coronary artery smooth muscle cells, I established evidence for the 
implication of the human Y chromosome in atherosclerosis and CAD. This study exposed 
the general under-expression of the transcripts from the Y chromosome in atherosclerotic 
cells implicating a loss or a repression of this chromosome in relation to CAD. 
Furthermore, RNA sequencing determined a significant downregulation of 7 transcripts 
182 
from Y chromosome genes, including RPS4Y1, USP9Y, DDX3Y, TXLNGY, NLGN4Y and 
PRKY. Most importantly, the PRKY subcellular localisation was revealed by RNA FISH 
in smooth muscle cells implicating a nuclear and a cytoplasmic expression. The 
bioinformatics analysis could not identify novel transcripts so the lincRNAs such as lnc-
KDM5D-4:1 was not identify in smooth muscle cell samples using RNA-seq. However, its 
expression was successfully determined in smooth muscle cells using qPCR analysis, 
showcasing a significant downregulation in atherosclerotic cells in comparison to the non-
atherosclerotic cells. 
Therefore, the combined results from Chapter 3 on lnc-KDM5D-4 as a potential regulator 
of PLIN2 and BIRC3 in hepatocytes, and Chapter 4 on lnc-KDM5D-4 downregulation in 
atherosclerotic coronary artery smooth muscle cells, suggest that the downregulation of 
lnc-KDM5D-4 could be linked to the inflammation of the vascular smooth muscle cells in 
CAD via, first, the lipid-droplets accumulation in hepatocytes triggered by the upregulation 
of PLIN2, and, secondly, the inhibition of apoptosis in vascular smooth muscle cells 
triggered by the upregulation of BIRC3. An overview of this potential involvement of lnc-
KDM5D-4 in atherosclerosis was proposed in Figure V.1. 
Figure V.1 has been removed at the author's request
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5.2 CONCLUSION 
In conclusion, this thesis is the first study on lincRNAs expressed on the human Y 
chromosome, and gene expression analysis, and has successfully unraveled the novel role 
of the Y-linked lincRNAs and their implication in CAD in men. The present study provide 
evidence for the potential involvement of one of these lincRNAs, lnc-KDM5D-4, in 
atherosclerosis and CAD, possibly through the lipid metabolism-associated gene PLIN2 in 
hepatocytes and dysregulation of apoptosis pathway through BIRC3 in coronary artery 
smooth muscle cells. Accordingly, this data suggests that lnc-KDM5D-4 may provide a 
novel molecular biomarker for atherosclerotic arteries, and could potentially lead to 
revolutionary treatment modalities on Y-linked lincRNA as therapeutic agents to 
manipulate CAD-causing genes in men. Thus, this thesis reinforces the idea that the human 
Y chromosome should be considered in future works in relation to CAD in men. 
5.3 FUTURE STUDIES 
The present study has provided the basis for numerous further studies. With the increasing 
knowledge of how lnc-KDM5D-4 may affect apoptosis, we could establish a better 
understanding of the precise molecular function of this new Y-specific lincRNA in CAD, 
non-alcoholic fatty liver, and liver cancer. Functional studies on lnc-KDM5D-4 in 
hepatocytes could be a potential avenue for further research to better understand the function 
into these cells, hence in steatosis-associated atherosclerosis and CAD. For instance, to 
confirm the interaction between lnc-KDM5D-4 and BIRC3 and to determine if the 
upregulation of BIRC3 is a cause or a mere consequence of the knock-down of lnc-KDM5D-
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4 in immortalised hepatocytes but also in coronary artery smooth muscle cells - such as 
Clonetics™ Human Vascular Smooth Muscle Cells (Lonza®) - the creation of an 
overexpression system targeting lnc-KDM5D-4 will be the best approach. If the interaction 
with BIRC3 - protein-coding gene located on chromosome 11 - was confirmed, this could 
support the potential action in trans of lnc-KDM5D-4 hypothesised in this thesis (Chapter 
3). This could also verify the implication of lnc-KDM5D-4 and BIRC3 in the inflammatory 
process of the artery wall in CAD via the potential inhibition of apoptosis in smooth muscle 
cells and foam cells. 
Experiments on validation of cellular apoptosis should be performed too. In this context, 
the well-known p53 tumor suppressor pathway, which can initiate the pathway of apoptosis 
(Vousden & Prives, 2009) should also be studied, as studies have previously demonstrated 
that the expression of some lincRNAs can be directly induced by p53 (Dimitrova et al., 
2014; Guttman et al., 2009; Huarte et al., 2010). Otherwise, the interaction of lnc-KDM5D-
4 with proteins such as the polycomb repressive complex-2 (PRC2), which has histone 
methyltransferase activity and is required for epigenetic silencing, should be investigated 
since PRC2 has become a model system for the study of the recruitment of chromatin 
remodeling factors by lncRNAs (Davidovich et al., 2015). In addition to that, a growing 
number of lncRNAs has been proposed to regulate gene expression in trans by redirecting 
the chromatin localisation of protein binding partners (Fatica & Bozzoni, 2014). 
Studying the lincRNAs expressed on the human Y chromosome implies working on a 
human cell model. Therefore, to further develop this study, working on human samples 
especially with male patients with CAD would be essential. Furthermore, with lnc-
KDM5D-4 being specific to the Y chromosome, it would be interesting to study its 
187 
expression changes between XY males and the dysgonosomia XYY syndrome, also known 
as Jacob’s syndrome, a chromosomal disorder that affect males caused by the presence of 
an extra Y chromosome. Therefore, there is still plenty to learn on Y chromosome-linked 
lincRNAs and studies underway may clarify and improve our understanding on 
cardiovascular biology and disease, such as CAD, and work on the elaboration of efficient 
therapeutic targets for the amelioration of heart disease. This is an exciting time for the 
study of RNA biology! 
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